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  Supplementation of zilpaterol hydrochloride (ZH; Zilmax
®
) to cattle has been suggested 
to have a negative impact on well-being of cattle. The objective of this study was to evaluate the 
hematological and serum biochemical profiles in feedlot heifers supplemented with ZH in a 
minimal stress environment.  Heifers were randomly assigned to one of two treatment groups: 
Control (CON no ZH), or ZH (supplemented with ZH at 8.33mg/kg of feed on a DM basis).  The 
study was conducted over a period of 25 d (-2 to 23), with three serum collection periods [-2 to 4 
d (ZH supplementation began on d 0); 13-16 d; and 21 to 23 d (withdrawal period)].  Serum 
samples were collected for a large animal chemistry profile analysis and blood samples were 
collected for hematological profile analysis. Liver, longissimus dorsi (LM), and biceps femoris 
(BF) samples were collected for vitamin E concentration analysis. There was a treatment effect 
for serum calcium (P = 0.008) with concentrations being greater in CON. A treatment effect was 
observed for serum bicarbonate (P = 0.03), with ZH having greater concentrations. A treatment x 
time interaction was observed for glucose (P = 0.02), BUN (P < 0.001), Cl (P = 0.04), creatinine 
(P ≤ 0.001), and creatine kinase (P≤ 0.001). In heifers fed ZH, creatinine, creatine kinase, and Cl 
concentrations in the serum were greater than CON heifers whereas glucose and BUN 
concentrations were decreased in the ZH heifers.  There was a treatment x time interaction for 
alkaline phosphatase (ALP, P < 0.001) and gamma-glutamyltransferase (GGT, P = 0.004). 
Overall, concentrations of ALP and GGT were greater in CON heifers. In the hematological 
profile, there was a treatment effect (P = 0.02) for hematocrit, where the ZH heifers had greater 
hematocrit. These data suggest that in this controlled environment, there were no negative 
impacts observed on the homeostasis with supplementation of ZH and most variables were 
within the normal homeostatic range of feedlot cattle.   
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Introduction 
 The supplementation of β-adrenergic agonists (β-AA) to livestock has been a topic of 
discussion for the past forty years. The β-AAs ractopamine hydrochloride (RH) and zilpaterol 
hydrochloride (ZH) are supplemented to swine and beef cattle to improve feed efficiency and 
promote increased lean muscle growth. The use of β-AAs has resulted in an increase in ADG 
(Montgomery et al., 2009) with decreases in DMI resulting in an increase in feed efficiency 
(Mersmann, 1998) and an increase in gain to feed ratio (Avendaño-Reyes et al., 2006). 
Administration of β-AAs has also been determined to result in increases in lean muscle in 
conjunction with decreases in fat deposition. 
In the past few years, concerns have developed due to personnel at the abattoir and 
feedlots observing lameness, slow movement, possible muscle fatigue, and even increased 
mortality. Some have suggested that these mobility issues could be a result of supplementation of 
ZH.   A recent study suggested a possible association between β-AA and an increase in both the 
cumulative risk and incidence of mortality in feedlot cattle (Loneragan et al., 2014).  
 The objective of this study was to conduct a very intensive and controlled trial to evaluate 
the hematological and serum biochemical profiles of feedlot heifers during supplementation and 
the withdrawal of ZH for the prescribed 23 d prior to harvest. When evaluating the profiles, 
alterations in serum metabolites and hematological profile were observed to determine if 
supplementation of ZH had a detrimental effect on the overall physiological health of the heifers.   
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Review of Literature 
I. Introduction of Beta- Adrenergic Agonists 
A. Definition of the Beta-Adrenergic Agonist 
The term “adrenergic” relates to nerve cells in which epinephrine and norepinephrine act 
as neurotransmitters. The β-adrenergic agonists (β-AA) bind to β-adrenergic receptors (β-AR) 
that are located on numerous cell types with in the body. β-adrenergic agonists are potent 
compounds that have been well documented in acting as growth promotants across many species. 
Agonists are defined as compounds that either directly or indirectly elicit a response similar to 
endogenous neurotransmitters by binding to β-receptors (Reece, 2015).  A commonly known 
response of an agonist is the relaxation of muscles, specifically around the airways.  Antagonists 
are the opposite of agonists and are defined as compounds that directly or indirectly prevent or 
block the effects of the endogenous neurotransmitters (Reece, 2015). When β-agonists bind to a 
receptor, they elicit a physiological response similar to the naturally occurring endogenous 
agonists circulating in the body.   The endogenous β-agonists commonly found are epinephrine,   
norepinephrine, and dopamine (Mersmann, 1998).  
 The physiological β-AAs, epinephrine and norepinephrine are classified as 
phenethylamines which are amines that are naturally occurring in the body and contain one 
amino group connected to a phenyl group via a two carbon chain (Pleadin et al 2012). 
Endogenous epinephrine and norepinephrine are classified as compounds called catecholamines. 
Catecholamines are compounds derived from the amino acids tyrosine and phenylalanine 
(Hadley and Levine, 2007).  The catecholamine norepinephrine is produced by the sympathetic 
nervous system and is synthesized from tyrosine.  Norepinephrine circulates in relativity high 
concentrations in the blood whereas; epinephrine is circulating in much lower concentrations 
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Figure 1 Chemical Structure of the β-AAs 
cimaterol, clenbuterol, L644,969, RH, 
salbutamol and ZH. (Pleadin et al., 2012). 
 
when compared to norepinephrine.  Norepinephrine is synthesized inside the nerve axon and is 
stored within the vesicles. It is released when an action potential travels down the nerve which 
depolarizes the membrane causing calcium to enter the axon (Hadley and Levine, 2007).  
Epinephrine is secreted from the medulla of the adrenal glands and is synthesized from 
norepinephrine.  
 The β-AAs ractopamine hydrochloride (RH), cimaterol, salbutamol, clenbuterol, and 
zilpaterol hydrochloride (ZH) are all examples of phenethylamines that have been studied in 
livestock. 
Beta-agonists chemical structures all 
possess the same phenyl group with the 
ethanolamine group. The ethanolamine group 
is composed of a two carbon chain with an 
alcohol group coming off the first carbon and 
an amine group off the second carbon. The 
major difference between these chemical 
structures is the different R groups that are 
attached to the amine group on the 
second carbon of the ethanolamine 
group (Figure 1).  
B. Physiological Responses in Humans 
β-adrenergic agonists were first developed as a means to help patients control their 
asthma (Crompton, 2006).   In humans, β-AAs are part of a group of medications that elicit a 
response like the naturally occurring catecholamines epinephrine and norepinephrine.  In 1956, 
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the first pressurized metered-dose inhaler (pMDI) was introduced to patients who suffered from 
asthma (Crompton, 2006).  The β-AA  isoprenaline was the primary compound in the most 
popular pMDI; however, it was determined that isoprenaline could be the possible cause of an  
increase in mortality in asthma patients  (Crompton, 2006).  Salbutamol was identified as a 
replacement for isoprenaline.  Today, salbutamol remains one of the most frequently prescribed 
short-acting β-agonists (SABA).  In the late 1980s, the first long-acting β-agonist (LABA), 
salmeterol, was introduced.  When first put into practice, clinicians claimed that salmeterol had 
clinically significant anti-inflammatory effects along with long bronchodilator action that lasted 
up to 12 hours (Twentyman et al., 1990).  These β-AAs continue to be the main drug in inhalers 
for asthma patients today.  The β-AAs elicit a response with the β-AR and relax constricted 
muscles around the airways, allowing the person to breathe easier.   
It has been reported that β-AAs could act as a potential treatment for patients that have 
muscle wasting disorders due to paralysis, muscular dystrophy and burn- and cancer-induced 
cachexia (Yang and McElligot, 1989).  Use of β-AAs has been reported to increase muscle mass, 
reduce fat deposition, and reduce recovery time due to injuries (Yang and McElligot, 1989).  
Increases in muscle mass and reduction in fat deposition are precisely the reason the animal 
agriculture industry is interested in using β-AAs.  
II. History of Beta-Agonists in Livestock 
 Cunningham (1965) reported the possibility of altering animal growth by administering 
various agents such as caffeine, epinephrine, theophylline, and nicotine in swine.  These agents 
presented either a direct or indirect effect on changing the intracellular concentration of cyclic 
adenosine monophosphate (cAMP). Cyclic AMP is incorporated into the actions of many 
hormones (i.e. growth hormone, epinephrine, and norepinephrine) on cellular physiological 
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processes by acting as a second messenger thus resulting in the activation or inactivation of 
certain enzymes when phosphorylated (Mersmann, 1998).  
Once it was discovered in humans that β-AAs could be used as a treatment method for 
patients with muscle wasting diseases, it was investigated for the use of livestock.  One of the 
first compounds to be developed was clenbuterol. This compound was developed using a non-
obese rat model to test the compounds’ capability to increase lean muscle growth (Moloney et 
al., 1991).   Clenbuterol administration also resulted in an increase in muscle and decrease in fat 
on the carcasses of steers (Ricks et al., 1984b) and in lambs (Baker et al., 1984).  Other 
compounds were synthesized (i.e. cimaterol, RH, and salbutamol) and studied in rodents and 
then livestock species. The response of these compounds varies by species, tissue type, dosage, 
duration of administration, and age of the animal (Mersmann, 1989; Anderson et al., 1991).  
This variation between compounds is why some 
have never been approved for use in livestock. To this 
day, the only compounds approved by the Food Drug 
Administration (FDA) are RH and ZH. Clenbuterol (a 
very potent compound) was never approved in livestock 
production in the United States because residues were 
found in the meat. In Italy, there have been reported 
cases of clenbuterol poisoning in patients that had eaten 
meat from supplemented animals (Brambilla et al., 
2000). Similar effects have been observed in Spain and 
France, where individuals consuming liver from animals 
Figure 2 Chemical structures of cimaterol, 
clenbuterol, and salbutamol (Chen et al., 
2005). 
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illegally-administered clenbuterol displayed symptoms of tremors, headaches, and dizziness 
(Martinez-Navarro, 1990; Salleras et al., 1995).        
Cimaterol was another potent β-AA that was never approved for livestock use. 
Clenbuterol, cimaterol, and salbutamol all have similar chemical structures (Figure 2) and when 
fed to cattle could result in residue levels in the kidneys and liver that can pose a threat to human 
health (Johnson et al., 2014). Since these compounds are not entire cleared from animal tissues, 
they are not approved for use in livestock production.      
A. Physiological Responses in Livestock     
With the population of the world increasing each year, higher demands have been placed 
on agricultural research to develop new technologies that will provide food for this expanding 
population. The United Nations Population Fund has developed three population projections 
called variants (a high, low, and in between). The medium variant predicts that the world 
population will grow to almost 10 billion by the middle of this century (UNFPA, 2015).   In the 
livestock industry, β-AAs have been a major focus to researchers since the early 1980s due to the 
benefits associated with increasing production efficiency.  Some of those benefits include but are 
not limited to: increase in muscle mass, decrease in adipose tissue, improved average daily gain 
(ADG), and an overall improvement of feed efficiency.  This increase in muscle mass and a 
decrease in fat deposition provide consumers with more lean meat without an increase in inputs.   
It is important for people to increase their protein intake and consuming lean meat is one of the 
primary sources of high quality protein.  
Several β-AAs have been tested to determine their impact on muscle growth. These β-
AAs include clenbuterol, cimaterol and RH.  In the early 1980s, data were published on 
modulation of growth in animals that were fed clenbuterol and cimaterol (Beermann et al., 1986; 
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Ricks et al. 1984a; Jones et al., 1985).  Oral administration of clenbuterol resulted in an increase 
in muscle mass and a decrease in fat deposition in growing cattle (Eisemann et al., 1988), swine 
(Ricks et al., 1984a), and sheep (Baker et al., 1984). Early use of β-AAs in swine production was 
focused on the compound cimaterol. Jones et al. (1985) observed that feed intake reduced 
linearly in swine as the amount of cimaterol administered increased. Dalrymple et al. (1984) 
reported no significant effect on feed intake. Dalrymple et al. (1985) and Beermann et al. (1986) 
reported that administration of cimaterol increased the rate of gain in lambs.  In swine, it was 
observed that administration of the β-AA cimaterol reduced back fat (Dalrymple et al. 1984; 
Jones et al. 1985).  In conjunction, it has also been reported that cimaterol administered to pigs 
causes an increase in muscle hypertrophy (Jones et al., 1985). In lambs (Baker et al. 1984; 
Beermann et al. 1986) and in steers (Ricks et al., 1984b) it has been noted that the carcass 
composition is altered towards more protein accretion and a reduction in fat deposition.   
Following the research of clenbuterol and cimaterol in livestock, the other β-AR agonists 
(such as RH, and ZH) were fed to different species and similar physiological effects were 
observed in livestock.  Studies have reported that other β-AAs (specifically RH and ZH)  have 
similar abilities to increase ADG and G:F as well as affecting several carcass characteristics 
(Moloney et al., 1990; Chikhou et al., 1993b).  Avendaño-Reyes et al. (2006) suggested that the 
supplementation of ZH and RH resulted in an overall improved feedlot performance of steers 
based on increases in ADG and G:F.  In addition, it was reported that hot carcass weight (HCW) 
and dressing percentage (DP) were improved with the supplementation of β- AAs.  The 
beneficial effects of β-AAs on growth performance have been observed in cattle, pigs, and sheep.  
Montgomery et al. (2009) reported the increases in G:F in feedlot cattle.  They also 
reported that supplementation of ZH resulted in an increased final body weight (BW) of both 
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steers and heifers.  Furthermore, they observed ADG and G:F  increased 36% and 28%, 
respectively, for the ZH supplemented steers and heifers (Montgomery et al., 2009).  When 
comparing the two β-AAs that the Food Drug Administration (FDA) have approved (RH and 
ZH), ZH tends to show more of an increase in ADG than RH (Avendaño-Reyes et al., 2006).  
Vasconcelos et al. (2008) observed that ZH-supplemented cattle increased ADG and G:F by 
approximately 28% when compared to the controls.  Literature also states that ZH fed cattle have 
improved DP compared to RH and non-supplemented cattle (Scramlin et al., 2010).  There have 
been suggested theories to why this phenomenon happens.  One possible explanation is the effect 
ZH has on fat metabolism in components of the animal that do not make up the carcass weight 
such as the hide or the viscera.  This theory is supported by the study by Scramlin et al. (2010)  
in which they reported cattle supplemented with ZH  had a reduction in total weight of kidney, 
pelvic, and heart (KPH) fat in the carcasses compared to steers fed RH and steers in the control 
group.  In addition, ZH-supplemented steers had reduced average hide weights compared to the 
RH steers and the control steers (Scramlin et al., 2010).   
Zilpaterol hydrochloride supplementation to feedlot cattle, DMI decreases compared to 
controls (Avendaño-Reyes et al., 2006; Vasconcelos et al., 2008).  In summary, β-AA 
administration results in an increase in muscle mass, decrease in fat, and overall improved 
feedlot performance in livestock.  
III. Development of Beta-Agonists on the market 
The multitude of physiological effects controlled by β-AR sparked interest in the biomedical 
community. This extensive interest led to the synthesis of numerous amounts of organic 
molecules that bind to β-ARs; some being agonists and others acting as antagonists (Mersmann, 
1998). Clenbuterol was the first β-AA to be studied, which is considered a synthetic analog of 
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epinephrine (Etherton., 2009). Clenbuterol supplementation resulted in an increase in DP, LM, 
and an overall increase in muscle mass in lambs (Baker et al., 1984) and in cattle (Miller et al., 
1988).  Cimaterol was studied next as it has a very similar chemical structure to clenbuterol and 
effects in lambs (Beermann et al., 1986, 1987; Kim et al., 1987) and in steers (Chikhou et al., 
1993b). Ractopamine is another compound that possesses β-AA activity and was noted for 
stimulating growth in swine (Anderson et al., 1987) and in beef cattle (Anderson et al., 1989). 
Previous research led to the development of ZH.  With the development of these synthetic 
compounds, there are very few that have actually been approved by the FDA for use in livestock.   
 A. Ractopamine Hydrochloride 
 Ractopamine hydrochloride was the first β-AA approved by the FDA for use in livestock. 
Ractopamine can be used as a β-AA for both swine and cattle. In swine, the use of RH was FDA 
approved on April 25, 2006. Ractopamine has the market name of Paylean
®
 and is manufactured 
by Elanco Animal Health based out of Greenfield, Indiana.  Swine supplemented RH are noted 
to have an increase in rate of weight gain, improved feed efficiency, and increase in overall 
leanness of the carcass (Anderson et al., 1987).  There are numerous positives to supplementing 
Paylean
®
 to finishing swine; however, it has also been reported (during the FDA approval trials) 
that administration of Paylean
®
 is associated with an increased number of injured or lame pigs 
during marketing (Marchant-Forde et al., 2003).  Paylean
® 
is utilized at the concentration of 4.96 
to 9.92 mg/kg of feed during the last 35 days prior to harvest. It is also important to note that 
Paylean
®
 be fed in a diet containing at least 16% crude protein (FDA, 2006a). With 
administration of Paylean
®
 there is no mandatory withdrawal period before harvest. 
 In cattle, the use of RH was FDA approved on June 13, 2003 under the tradename 
Optaflexx
®
. Optaflexx
®
 is also manufactured by the company Elanco Animal Health. This 
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product also results in the increase in feed efficiency and weight gain but in feedlot cattle instead 
of swine. Optaflexx
® 
also results in an increase in live weight (LW), HCW, and DP (observed in 
the FDA approval study). It has different severities at different doses. Just like Paylean
®
, 
Optaflexx
®
 is supplemented as part of a complete feed but at the concentrations of 8.2 to 24.6 
grams per ton during the last 28 to 42 days on feed. However; Optaflexx
® 
can also be top dressed 
at 70 to 400 milligrams per head per day when administered to cattle. There is no withdrawal 
period for administration of Optaflexx
®
 (FDA, 2009). With the administration of Optaflexx
®
, 
there have been no dramatic changes in meat quality. This product has been reported to have no 
effect on meat color, the degree of marbling, or the percentage of carcasses that grade USDA 
Choice (Quinn et al., 2008). In addition, Quinn et al. (2008) also observed no significant 
difference in Warner-Bratzler shear force values between the controls and cattle treated with 
Optaflexx
®
.  Another study observed that RH-supplemented steers (RH = 4.83 kg/cm
2
) had 
significantly greater shear force values compared to the controls (Control = 4.39 kg/cm
2
)  
(Avendano-Reyes et al., 2006).  Overall, supplementation of Optaflexx
®
 results in an increase in 
feed efficiency and ADG but does not have much of an effect on carcass characteristics.   
B. Zilpaterol Hydrochloride 
 Zilpaterol hydrochloride was approved for supplementation to cattle on August 10, 2006. 
Its market name is Zilmax
®
 and is manufactured by Merck Animal Health. Zilmax
®
 is 
supplemented at 8.33 mg/kg on a 100% DM basis for the last 20 days prior to harvest followed 
by a 3 day withdrawal period.  Supplementation of Zilmax
®
 has been shown to increase HCW, 
LW, DP, and yield grade (Avendano-Reyes et al., 2006; Beckett et al., 2009; Rathmann et al., 
2009). Unlike Optaflexx
®
, there is a reported difference in meat quality in cattle supplemented 
Zilmax
®
. Zilmax
®
 supplementation resulted in a lower percentage of carcasses that grade USDA 
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Prime and Top Choice when compared to control cattle (Elam et al., 2009). In addition, there has 
been an observed increase in the percentage of cattle grading USDA Select.  Not only does 
Zilmax
®
 affect the marbling scores but it has an effect on tenderness. Studies have shown that 
cattle supplemented with Zilmax
®
 have increased shear force values (Rathmann et al., 2009; 
Leheska et al., 2009).  Leheska et al. (2009) observed on average a 0.7 kg increase in shear force 
values in the LM with Zilmax
®
 supplemented beef cattle.  
Zilmax
®
 was voluntarily taken off the market as personnel at various abattoirs throughout the 
United States had noted cattle being tender footed and lame. These accusations were not 
scientifically proven and were not taken lightly. Several beef packing companies announced they 
would no longer accept cattle supplemented with Zilmax
®
. Since packers were no longer 
accepting these cattle, Merck voluntarily removed their product from the market to do further 
investigations to the accusations that were made.   
IV. Mode of Action of Beta-Agonists        
A.  Adrenergic Receptors 
There are two types of AR: α-adrenergic and β-adrenergic (Mersmann, 1998).  In order 
for β-AAs to elicit a biological effect the β-AA  must bind to a β-AR (Hadley and Levine, 2007).  
These receptors are naturally occurring in the body and the catecholamines epinephrine (EPI) 
and norepinephrine (NEPI) are the naturally occurring ligands that bind to these receptors.  
Epinephrine is a ligand for both of the adrenergic agonist receptors but the net response to 
epinephrine depends on the presence of the receptors.  One of the observed differences between 
α-AR and β-AR is the type of G-coupled protein to which each binds.  The β-AR is important in 
regulating cell metabolism by coupling with the Gs-protein.  The α-AR has an opposing effect as 
it is coupled with the Gi-protein or inhibitory protein (Johnson et al., 2014).   
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In the livestock industry β-ARs are the receptors of focus.  The β-ARs can be subdivided 
even further into β1-AR, β2-AR, and β3-AR whereas α-ARs are subdivided into α1-AR and α2-
AR.  Almost all cells in the mammalian body contain β-AR but the abundance and distribution of 
each receptor subtype are varied between the different tissues of the same species.  This suggests 
why scientists have observed differences in magnitudes of biological effects across tissues in the 
same animal  (Johnson et al., 2014).   
 The α-AR subtypes have opposite effects than β-AR.  The α1-ARs are found in blood 
vessels that serve the kidneys, abdominal viscera, skin, mucosae, and salivary glands (Reece et 
al., 2015)..  Instead of dilating the blood vessels like β-ARs, the α1-ARs constrict the blood 
vessels and visceral organ sphincters (Reece et al., 2015).  The α2-ARs receptors are located in 
the membrane of adrenergic axon terminals, pancreas, and in blood platelets.  The α2-ARs inhibit 
the release of norepinephrine from the adrenergic terminals, inhibit insulin secretion from the 
pancreas, as well as promote blood clotting (Reece et al., 2015).  
The three subtypes of β-ARs are not present in all tissues but certain receptors are 
prevalent in some tissues more than others.  For example, β1-AR is primarily located in the heart 
but can also be identified in the kidneys and some adipose tissue.  When binding occurs with the 
β1-ARs, the results are an increase in heart rate along with an increase in renin production by the 
kidneys (Reece et al., 2015).  The β2-ARs have been on every mammalian cell in the body 
(Mersmann, 1998).  The β2-ARs are located abundantly on blood vessels serving the heart, liver, 
and skeletal muscle.  When bound, numerous responses occur, including dilation of blood 
vessels and bronchioles, along with relaxation of smooth muscle of the digestive and urinary 
organs (Reece et al., 2015).  The last subtype of β-receptors (β3-AR) is primarily located in 
adipose tissue.  The β3-ARs stimulate lipolysis in adipose tissue. Sillence et al. (2005) have 
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suggested the possibility that a fourth β-AR subtype may exist only in porcine adipose tissue.  
However, no unique sequence has yet been determined for this suggested receptor whereas, the 
other three subtypes have been cloned and sequenced (Johnson et al., 2014).   
 All the subtypes of β-ARs possess seven hydrophobic, transmembrane-spanning domains 
that form loops both extracellular and intracellular on the surface of most mammalian cells.  The 
β-ARs are also composed of more than 400 amino acids.  The binding of ligands occur on the 
extracellular portion of the loop which then initiates a conformational change of this membrane-
bound receptor.  These receptors are part of a large family of G-coupled protein receptors that 
elicit a response by binding to Gs proteins.  Once the β-AR is coupled with a Gs protein, the 
enzyme adenylate cyclase is activated to cause synthesis of cyclic adenosine monophosphate 
(cAMP).  Cyclic adenosine monophosphate is responsible for regulation of the catalytic subunit 
protein kinase A (PKA).  Protein kinase A is known for being vital to many biological functions 
as it results in the phosphorylation of key enzymes (Mersmann, 1998).  This phosphorylation can 
lead to either activation or inactivation of various enzymes.  In addition, PKA targets 
transcription factors that regulate the transcription of DNA to mRNA.  For example, the cAMP 
response element binding protein (CREB) is phosphorylated by PKA.  The CREB binds to a 
cAMP response element which then stimulates the transcription of the regulatory part of that 
gene (Mersmann, 1998).  This increase in transcriptional activity provides the mechanism for β-
AR agonist-mediated transcription of many other genes.  
 Protein kinase A not only targets phosphorylation within the extracellular domains but it 
also targets intracellular domains.  In the intracellular domains, phosphorylation causes the 
uncoupling of the β-AR from the Gs protein.  This uncoupling causes the inactivation of the 
receptor, also known as desensitization (Mills and Mersmann, 1995).   
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B.  Impact on Muscle 
In beef cattle, muscle hypertrophy is the result of increased protein synthesis and/or 
reduced protein turnover (Mersmann, 1998).  Postnatal muscle growth has been a major focus 
related as β-AAs effects are the increase in muscle mass.  Skeletal muscle hypertrophy is 
obtained by an expected increase in protein accretion, a decrease in protein degradation, or a 
combination of both (Yang and McElligot, 1989; Moloney et al., 1991; Mersmann, 1998).  There 
are limited data on measuring protein degradation; instead research has focused on protease 
activities (specifically calpains) in muscle from animals treated with β-AAs.  Researchers have 
reported that several protease activities are often reduced, or the protease inhibitors (calpastatins) 
are increased by β-AAs administration (Wang and Beermann, 1988; Kretchmar et al., 1990, 
Koohmaraie et al., 1991; Bardsley et al., 1992; Sainz et al., 1993).   
With supplementation of β-AAs, a rapid growth in muscle is observed. For example, ZH 
administration results in an average of 11- 15 kg of more muscle on the carcass compared to the 
cattle not given ZH (Merck Animal Health, 2015). The duration of administration also has an 
effect on the response of increases in muscle growth. With ZH, it has been reported that 
supplementation past the recommend 20 days does not have any significant effect on carcass 
measurements (Vasconcelos et al., 2008).   
Another impact β-AA administration has on muscles is the change in muscle fiber type.  
Studies have indicated that type II fibers (glycolytic) fibers are more likely to be altered with β-
AA (cimaterol) administration than type I (oxidative) fibers (Beermann et al., 1987; Kim et al., 
1987).   Baxa et al. (2010) indicated that ZH increased the abundance of mRNA of myosin heavy 
chain IIX in cattle which would ultimately result in an increase in larger fiber diameters. In 
sheep, the size of type II fibers has consistently increased by 10-50% with β-AA administration 
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(Beermann et al., 1987; Kim et al., 1987).  The effects of alterations in type I fibers are more 
varied than type II.  In sheep, Kim et al. (1987) reported that type I fibers were not affected by β-
AA administrations whereas Beermann et al., (1987) reported that type I fibers increase in size.  
C.  Impact on Fat 
 Ricks et al. (1984b) have termed β-AAs (specifically clenbuterol) as repartitioning agents 
due to the fact β-AA shift nutrients towards muscle growth and away from adipose deposition. 
The reduction in fat has been well documented across multiple livestock species with the various 
β-AAs (Ricks et al., 1984a; Beermann et al., 1986; Cromwell et al., 1988; Anderson et al., 1991; 
Moloney et al., 1990; Elam et al., 2009).  Reduction in adipose is not limited to any specific 
depot. Reduced adipose depositions has been reported in subcutaneous, visceral, inter- and intra- 
muscular depots (Quirke et al., 1988; Moloney et al., 1990; Leheska et al., 2009; Rathman et al., 
2009).  Reduction in kidney, pelvic and heart fat (KPH), 12
th
 rib back fat, and marbling score 
have been the most documented incidences of alterations in fat. The reduction in marbling score 
has an impact on the quality grades of beef carcasses (Elam et al. 2009). 
 The reduction in fat is a result of β-AAs activating a hormone-sensitive lipase that 
stimulates degradation of the triglycerides in the adipocytes into glycerol and free fatty acids 
(Fain and Garcia-Sainz, 1983).  Other studies have suggested that chronic treatment of β-AAs 
block lipogenesis (Smith et al., 1987; Liu et al., 1988) through the loss of key signaling enzymes 
(Steinberg, 1976).  However, contradictions between agonists and species have been reported on 
the effect on lipogenesis.  Agonists that cause reduction in adipose and bind to the β-ARs may 
result in minimal effects on lipid metabolism measured in-vitro within the same species 
(Spurlock et al., 1993; Mills and Mersmann, 1995).  The administration of RH has been reported 
to increase lipolysis and decrease lipogenesis in swine (Merkel et al., 1987; Liu et al., 1988) 
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while other compounds like clenbuterol (Mersmann, 1987a) only affect the lipolytic rate.  
Zilpaterol hydrochloride is suggested to have a larger repartitioning effect on fat metabolism 
than RH (Scramlin et al., 2010).      
 It has also been suggested that an elevation of plasma nonesterified fatty acid 
concentration after administration of a β-AA results in the stimulation of the adipocyte lipolytic 
system.  In swine, several β-AAs elevate the plasma nonesterified fatty acid concentrations 
(Mersmann, 1987b). Blum and Flueckiger (1988) along with Eisemann et al. (1988) observed the 
same response in cattle.   
V. Impact on Carcass Traits 
A.  Carcass Characteristics 
 The impact of administration of β-AAs on carcass characteristics is well documented and 
is where the most noticeable alterations occur. These alterations are evident across a majority of 
β-AAs; the severity depends upon the β-AA and amount that is used. One of the most prevalent 
effects of the use of β-AAs in livestock is the increase in HCW. An increase in HCW could 
result in an increase in yield grade 1 and 2 carcasses due to β-AA administration causing a 
decreased 12
th
 rib fat and increased LM area size.  A lower yield grade is desirable in carcass as 
it represents a higher percentage of boneless closely trimmed retail cuts.  Beckett et al. (2009) 
observed an increase in USDA stamped yield grade 1 and 2 carcasses in conjunction with a 
reduction in yield grade 3 and 4 when feeding ZH. In another study, yield grades were decreased 
in ZH carcasses compared to the RH and controlled carcasses (Scramlin et al., 2010).  These 
observed changes in yield grade are in direct correlation to the four components of the yield 
grade equation (12
th
 rib fat, HCW, LM area, and KPH). With β-AA administration, an increase 
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in LM area and decreases in the fat at the 12
th
 rib and KPH cause the observed increase in lower 
numerical yield grades.   
Zilpaterol hydrochloride supplementation is characterized as having a strong effect on the 
carcass cutout.  Rathmann et al. (2009) observed that 22 of the 33 subprimal cuts from a beef 
carcass displayed a positive difference (meaning an increase in lean yield) between the control 
and ZH-supplemented cattle.  Although research shows that ZH elicits a response of an increase 
in weight within every whole primal region of the carcass, the most consistent area affected is 
the round (Rathmann et al., 2009).  Rathmann et al. (2009) also observed an increase in the 
percentage yield for every subprimal cut from the round in ZH fed steers.  The LM is another 
muscle that consistently increases in size with ZH supplementation; however this is not true for 
all β-AAs.  The LM area is larger in ZH fed cattle whereas RH fed steers do not differ from the 
control steers (Avendaño-Reyes et al., 2006).  This increase in skeletal muscle tissue is the most 
consistent biological effect of ZH supplementation and this confirms many of the well 
documented carcass trait changes that have been observed (Becket et al. 2009; Leheska et al., 
2009; Montgomery et al., 2009; Rathmann et al., 2009).  
 Another factor that affects yield grade values is the amount of fat on a carcass.  It has 
been observed that the 12
th
 rib back fat is reduced along with other adipose tissue depots 
decreasing in size with the feeding of β-AAs (Quirke et al., 1988; Moloney et al., 1990; Leheska 
et al., 2009; Rathman et al., 2009).  Ricks et al. (1984b) conducted a study to determine the 
effects of clenbuterol fed at different concentrations in steers on fat and muscle deposition.  
Clenbuterol fed at 10 and 500 mg/hd/d reduced KPH by 23 and 33% and reduced 12
th
 rib back 
fat by 35 and 42%, respectively.  This result shows that not only does the reduction of fat content 
occur subcutaneously but occurs in internal depots as well.    
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B.  Meat Quality 
The use of β-AA has been important in increasing production of a lean source of animal 
protein; however, this increase in yields could potentially change the palatability and quality of 
the product.  Research has shown that when β-AAs are fed meat quality grades tend to decrease.  
When ZH is fed, studies have shown that there is a reduction in marbling score.  Elam et al. 
(2009) observed that the percentage of carcasses that graded USDA Prime and Top Choice were 
lower in the ZH-fed cattle.  In direct correlation, there was an increase in the percentage of cattle 
that graded USDA Select.  As the duration of ZH feeding increased these effects continued to 
increase or decrease in a linear fashion (Elam et al., 2009).  
Not only does the supplementation of β-AAs have an effect on the marbling score but 
differences in tenderness have been identified.  In general, β-AAs have shown an increase in 
Warner-Bratzler Shear Force (WBSF) values when compared to the controls. Some β-AAs seem 
to have greater changes on WBSF than others. This was evident when comparing clenbuterol, 
RH and ZH-fed cattle to the control group.  Strydom et al. (2009) discovered that clenbuterol had 
the greatest effect on WBSF especially on the longissimus lumborum (LL) followed by ZH. 
Clenbuterol resulted in greater WBSF values. With aging there was a similar decrease in WBSF 
observed in the controls as well as the ZH and RH-fed cattle.  Clenbuterol, however, resulted in a 
significantly lower reduction WBSF than other treatments during aging (Strydom et al., 2009).  
In general, ZH supplementation results in an increase in WBSF values across all aging periods 
compared to control cattle (Rathmann et al., 2009). Quinn et al. (2008) observed no significant 
difference in shear force values in cattle treated with RH.  Leheska et al. (2009) observed that 
ZH-fed steers increased WBSF values by 22% and heifers increased by 24%, respectively.  
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There are a few studies that had a trained sensory panel to determine if β-AA- treated 
groups displayed a change in tenderness or juiciness that consumers could identify.  Overall 
tenderness in one sensory panel decreased 11% and flavor intensity scores decreased by 4% 
when cattle were fed ZH (Leheska et al., 2009).  Leheska et al. (2009) mirrored what Hilton et al. 
(2009) observed. Hilton et al. (2009) observed the same decrease in the trained sensory panel 
juiciness, tenderness, and the beef flavor intensity.         
VI. Impact on Animal Well Being    
There are currently very little data present on the use of β-AAs associated with a 
compromises animal welfare.  Within the past couple years there have been observed 
abnormalities in the mobility of cattle upon arrival at the abattoirs. These reported incidences 
have generated concern in the beef industry. Personnel at various abattoirs throughout the United 
States observed cattle being nonambulatory or slow and having difficulty moving as well as 
cattle that appeared to have sloughed hoof walls which has raised concerns (Thomson et al., 
2015).  Some individuals believe there is a relationship between these mobility issues and the use 
of the β-AA ZH.  There are insufficient data to establish an actual causal relationship between 
the two.  It has been suggested that the cattle supplemented with ZH are at a greater risk in 
developing the mobility issues at the abattoirs (Thomson et al., 2015).  
Thomson et al. (2015) suggested that many of the cattle that present mobility issues upon 
arrival at the abattoirs have clinical signs that are similar to those of pigs with fatigued pig 
syndrome (FPS).  Fatigued pig syndrome-affected pigs become nonambulatory without any 
noticeable trauma, injury, or disease and the pigs refuse to move (Marchant-Forde et al., 2003). 
This syndrome is associated with many factors including; but not limited to, stressful handling 
and the supplementation of the β-AA RH in doses that are on the higher end of the approved 
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range.  Thomson et al. (2015) hypothesized that those cattle upon arrival at the abattoirs with 
mobility problems may have a similar condition as FPS due to all the clinical similarities.  A 
study done by Marchant-Forde et al. (2003) suggested that FPS is associated with finishing pigs 
fed RH.  Pigs had elevated heart rates and increased concentrations of circulating catecholamines 
such as epinephrine and norepinephrine, which resulted in behavioral changes that made 
handling the pigs more difficult at the time of transport to the abattoirs and less tolerant of stress.  
Following this study, the manufacturer of RH reduced the recommended dose and added a 
caution on the label that the use of RH may result in an increased risk of injured or fatigued pigs 
(Elanco, 2016).  This association of FPS with the use of RH leads to speculation that β-AAs 
could have the same effect on cattle resulting in FCS. 
It has been suggested that ZH supplementation could be a compounding factor of 
“muscle fatigue.” Studies have reported that ZH enhances the growth of the “fast-twitch” or 
white muscle fibers (Johnson et al., 2014).  The fast twitch muscle fibers are used for short 
durations of muscle contractions (phasic). These muscle fibers are not used for endurance so they 
fatigue more easily than the other muscle fiber types.  Baxa et al. (2010) observed that when 
cattle were fed ZH there was a differential response in the mRNA abundance of myosin heavy 
chain.  This resulted in the transition away from slower twitch fibers to faster twitch fibers which 
could ultimately be the source of increase in skeletal muscle fiber diameters in carcasses that are 
fed ZH. This transition to white muscle fibers could be the cause for the observation of muscle 
fatigue when cattle are placed under stressful situations. White muscle fibers are phasic and 
therefore are more prone to fatigue. If cattle are being stressed and they have transitioned to 
more white muscle fibers due to β-AA supplementation then the muscles are expected to fatigue 
faster.   
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Alterations in body temperature can be indicative of negative physiological functions and 
could lead to potential animal welfare issues. Environmental temperatures are vital in regulating 
core body temperature which promotes better productivity in livestock. When livestock are under 
heat stress their body temperatures become elevated which could ultimately hinder overall 
production. A study by Marcias-Cruz et al. (2010) used ewe lambs to look at a possible 
correlation between body temperature and ZH supplementation during heat stress conditions. 
Temperatures where collected from the head, rump, belly, and right flank of the lambs. Marcias-
Cruiz et al. (2010) observed that lambs fed ZH resulted in higher temperatures in the belly and 
flank whereas there were no differences in the head and rump. It was suggested that the increase 
in temperature could be a result to changes in the rumen and intestinal environment when ZH 
was fed.  
Another trial (Boyd et al. 2015) examined the effects of shading and feeding ZH to 
finishing steers.  What Boyd et al. (2015) discovered was contradictory to their theory that ZH 
supplementation increases the heat load on the animal.  The average and maximum body 
temperature was lower in the cattle fed ZH than the controls, even with the different housing.  
There were two types of housing in this trial- open lot and shaded.  The results of the control 
cattle were what they expected and the shaded cattle had lower average and maximum body 
temperature than the open lots.  With feeding of ZH they observed the very opposite.  The cattle 
in the open lots had lower average and maximum body temperature than the shaded cattle.  It has 
been suggested that the addition of a β-AA could result in an increase in blood flow to skeletal 
muscle and adipose tissues (Mersmann, 1998).  Therefore, it could be speculated that more blood 
moving away from the body’s core towards muscle and fat could aid in cooling the animal and 
result in decreased body temperatures through conductive heat loss (Boyd et al., 2015).   
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When analyzing stress, the steroid hormone cortisol is often measured. Cortisol is 
considered an adrenocortical steroid and due to the hyperglycemic effect; cortisol-like substances 
are given the name glucocorticoids (Reece et al., 2015).  The hyperglycemic effect occurs due to 
glucocorticoids reducing the affinity of insulin in certain cells.  Glucocorticoids also serve many 
other metabolic functions in the body which include alterations in lipid, protein and carbohydrate 
metabolism.  Cortisol is known as the “stress hormone” and is in higher concentrations when an 
individual is under stress.  Cortisol provokes the cell to produce glucose from proteins and fatty 
acids through the process of gluconeogenesis.  Ultimately, cortisol saves the glucose for the brain 
and forces the body to use other alternatives for energy.  In addition, cortisol increases blood 
pressure which results in an increase in blood flow to distribute the glucose and other nutrients as 
fast as possible to the cells (Reece et al., 2015).    
There are limited data on the correlation of cortisol concentrations and β-AA.  Marchant-
Forde et al. (2003) observed in pigs fed RH that there was no significant difference between the 
RH fed group and controls in the percentage change of cortisol concentrations from the baseline, 
even when responding to transportation stress.  Another study indicated similar results, where 
plasma cortisol concentrations were not affected by β-AAs use in lambs (Li et al., 2000). 
Bruckmaier et al. (1992) conducted research on the responses of calves to exercise during 
feeding the β-AA clenbuterol and observed cortisol concentrations did not change.   
VII. Blood Variable Changes due to Beta- Agonists 
 There is very limited information on the effects of β-AAs on the metabolic profile of 
livestock and what is available is very inconsistent.  
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A. Glucose  
Glucose is an important component of proper cell function.  It provides cells with a 
source of energy. Blood glucose concentrations in association with β-AAs are not consistent in 
the literature.  Researchers observed that whole-blood concentrations of glucose decreased with 
the supplementation of ZH over time while controls remained constant in cattle supplemented 
with ZH (Bibber-Krueger et al., 2015).  It is suggested that ZH administration may result in the 
secretion of stored red blood cells in the spleen via activation of the β-ARs, which would result 
in an increased number of cells in circulation to metabolize glucose (Bibber-Krueger et al., 
2015). Evaluating clenbuterol, Eisemann et al. (1988) observed an initial increase in glucose, 
however, after day nine of feeding clenbuterol, glucose concentration was not different between 
treatments.  These results suggest there is the initial response of glucose metabolism to the 
supplementation of the β-AA but cells eventually become desensitized and there is no longer a 
response.  Another study conducted with feedlot lambs observed no effects on blood glucose 
with administration of RH or ZH (López-Carlos et al., 2010). A study observing the effects of 
RH on genetically obese and lean pigs reported no difference in glucose concentration between 
the groups (Yen et al., 1990).   
B. Insulin  
Insulin is secreted by the pancreas and is vital in the regulation of blood concentration of 
glucose.   Effects of β-AAs on insulin concentrations have varied.  O’Conner et al. (1991) 
observed in lambs that concentrations of insulin were elevated after 2 hours of cimaterol 
supplementation whereas in 3 to 6 weeks insulin concentrations decreased.  O’Conner et al. 
(1991) suggested that the acute response in the elevation of insulin was a result of stimulation of 
glycogenolysis and lipolysis by cimaterol. It has also been suggested that the repartitioning 
24 
 
effects of β-AAs may be caused by opposing effects on insulin sensitivity in adipose versus 
muscle tissues (Anderson et al., 1991).  Insulin is associated with increased protein synthesis and 
decreased proteolysis in muscle and increased lipid synthesis and decreased lipolysis in adipose, 
the inhibitory effects of insulin on adipose and the enhancement on muscle tissue would 
repartition nutrients towards lean tissue growth (Anderson et al.,1991).   Liu and Mills (1990) 
observed a reduction in insulin sensitivity in adipocytes in pigs supplemented with RH.  
However, Beermann (1987) reported no change in insulin sensitivity in lambs despite the fact 
that insulin concentrations decreased. In summary the effects of β-AAs on insulin concentrations 
are varied.  
C. Blood Urea Nitrogen 
Blood urea nitrogen (BUN) is a measurement of the amount of nitrogen found in the 
blood that comes from the waste product of urea.  Urea is made when protein is broken down in 
the body and secreted from the liver.  In the literature BUN is consistently lower in animals 
administered a β-AA.  Steers administered clenbuterol presented depressed BUN concentrations 
(Ricks et al., 1984b).  In correlation BUN concentrations, another study revealed feeding cattle 
ZH resulted in decreased plasma urea nitrogen (PUN) concentrations (Bibber-Krueger et al., 
2015). Decreased BUN or PUN concentrations are indicative of increased nitrogen retention.  
Increased nitrogen retention is a reflection of decreased protein catabolism in skeletal muscle 
when β-AAs are administered (Bibber-Krueger et al., 2015).  It has been a general finding that 
administration of β-AAs results in an increase in nitrogen retention which correlates to muscle 
accretion (specifically the increase in carcass weight and LM area) in ruminants (Williams et al., 
1987).   
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D. Creatinine  
          Creatinine is a product of normal functioning muscle metabolism and is considered a 
measurement of muscle mass.  It is produced from the breakdown of creatine. According to 
Istasse et al. (1990) there is a positive correlation between creatinine concentrations and carcass 
weight, DP, and the proportion of lean mass in the carcass with administration of β-AAs.  The 
literature for creatinine is well documented in saying that with the administration of a β-AA there 
is an increase in serum concentrations of creatinine (Chikhou et al., 1993a, and Quirke et al., 
1988). It has been suggested that the alterations in the creatine pool are most likely the result in 
the changes in total muscle mass (Perrone et al., 1992).  
E. Creatine Phosphokinase  
   Creatine phosphokinase (CPK) or creatine kinase is a catalyst for the reversible reaction of 
creatine to phosphocreatine in which the by-product is creatinine.  Cattle fed ZH have increased 
concentrations of CPK which was observed in many studies including the FDA approval studies 
(FDA, 2006b). Thompson et al. (2015) evaluated two cattle from a shipment of 200 head that 
were fed ZH in accordance with the label directions and markedly increased concentrations of 
CPK from the reference ranges were observed. However, these two cattle evaluated were 
considered downer cattle and other cattle maintained in a typical feedlot setting with minimal 
stress did not differ significantly between the β-AA fed cattle and the controls.   The CPK 
concentrations are increased in swine that are supplemented with ractopamine (Athayde et al., 
2013). Elevated concentrations of CPK would be expected in cattle fed β-AAs due to the 
increase in muscle mass. The creatine pool increases with increasing muscle size, therefore, more 
CPK is required to catalyze the reaction. Since β-AA-fed cattle have documented increases in 
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creatinine, it is known CPK also increased to catalyze the reaction to produce creatinine as a by-
product. 
F. Proteins  
 Plasma is composed of 91-92% water and the rest is solid constituents. Of these 
constituents, plasma proteins are the most abundant. The two major classes of proteins in the 
plasma are albumin and globulin. The function of albumin is to regulate and maintain osmotic 
pressure of the blood and to act as a transporter of various substances (Reece et al., 2015).  
Furthermore, albumin is associated with bicarbonate and phosphate as a buffer for the 
extracellular fluid.  Globulins main function is in immune response (Reece et al., 2015). 
Together, albumin and globulin make the total protein concentration in the blood.  There is 
limited information on administration of β-AAs and protein concentrations. A study by Ricks et 
al. (1984b) observed no significant alterations in albumin and total protein in steers administered 
clenbuterol.  
G. Lactate 
 When cells have a high demand for glucose utilization lactate is produced.  Lactate is 
produced when pyruvate is reduced during glycolysis due to the insufficient supply of oxygen, 
like when skeletal muscles are contracting (Reece et al., 2015).  Blum and Flueckiger (1988) 
observed in calves an increase in lactate concentrations up to 10 hours after the administration of 
the β-AAs.  Eisemann et al. (1988) presented similar findings when administrating clenbuterol to 
steers. This increase in lactate suggests a possible increase in peripheral glycolysis.  Furthermore, 
ZH supplementation may have an increase in the demand for glucose by stimulating 
glycogenolysis and glycolysis (Bibber-Krueger et al., 2015).  Therefore, this would result in an 
increase of lactate concentrations.     
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H. β-hydroxybutyrate 
 Skeletal muscles derive a significant amount of their energy requirements from oxidation 
of ketone bodies into acetylCoA (Reece et al., 2015).  Beta-hydroxybutyrate is one of those 
ketone bodies. It is produced from the metabolism of non-essential fatty acids via the liver. 
Elevated concentrations are usually indicative of a negative energy balance. Both Bibber-
Krueger et al. (2015) and Eisemann et al. (1988) observed no significant differences when a β-
AA was administered to cattle.  These observations suggest that β-hydroxybutyrate is being 
metabolized efficiently enough to avoid accumulation in the blood (Bibber-Krueger et al., 2015). 
I. Minerals 
 Minerals such as calcium, phosphorus, sodium, and potassium are essential for many 
cellular functions.  The major function of calcium is in skeletal muscle and bone formation along 
with initiating muscle contraction.  Phosphorus is involved in every major metabolic pathway in 
the body due to it being a component of phospholipids and adenosine triphosphate (ATP).  
Sodium has a primary function of acid-base balance of the body. Lastly, the major function of 
potassium is determining the resting potential of a membrane (Reece et al., 2015).  This being 
said, there are extremely limited data published on the connection between mineral 
concentrations and the administration of β-AAs in livestock. Ricks et al. (1984b) reported no 
obvious abnormalities with calcium and phosphorus concentrations in steers administered 
clenbuterol.  It has been observed in horses that calcium and potassium were elevated and 
sodium was decreased in the ZH group (Wagner et al., 2008). The authors were unable to give an 
explanation as to why this phenomenon happened.   
 
 
28 
 
J. Liver Enzymes  
 Liver enzyme concentrations are used as an indicator of tissue damage in the liver. There 
is very little literature on the alteration of liver enzyme concentrations when administered β-AAs. 
Ricks et al. (1984b) reported no abnormalities in the enzyme alkaline phosphatase in Hereford 
steers administered clenbuterol.  Another study by Chikhou et al. (1993a) observed elevated 
concentrations of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) with β-
AA feeding. However, the concentrations of these enzymes were still within the range of normal 
healthy cattle.  In addition, these studies revealed neither liver nor heart damage occurred in the 
animals. There have been elevations in some liver enzymes observed with administration of β-
AAs but concentrations are still within the biological range for healthy animals.   
VIII. Conclusion 
         In conclusion, the most positive attributes in the use of β-AAs are an increase in feed 
efficiency, ADG, DP, HCW, LM area, coupled with a decrease in fat deposition. These 
characteristics are vital to continue providing consumers with a viable animal protein source. 
Harvesting animals with more lean meat is vital in reaching consumers demands; however, the 
use of β-AAs raises the concern of animal well-being. They must be fed at the appropriate 
concentrations or we might see more lameness in treated animals. Ractopamine-supplemented 
pigs have an increase in fatigue during handling (Marchant-Forde et al. 2003). Some believe 
(Thompson et al., 2015) we are seeing similar effects with cattle supplemented with ZH. 
However, the changes that are observed in the animals metabolically are in direct correlation 
with protein accretion which ultimately leads to the increase in muscle mass. All other metabolic 
parameters are not changing drastically enough to constitute any animal well-being concerns.   
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 The objective of the present study was to conduct a very intensive and controlled trial to 
evaluate the impact of ZH supplementation on hematological as well as serum biochemistry 
profiles. 
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Materials and Methods 
 
Experimental design 
 
All the experimental procedures were approved by the Institutional Animal Care and Use 
Committee at the University of Nebraska (IACUC #902) along with being in compliance with 
the Guide for the Care and Use of Agricultural Animal in Research and Teaching Third Edition 
(2010).  
 Twenty crossbred yearling heifers (556±7 kg initial BW) utilized for this study were 
obtained from the University of Nebraska Agricultural Research and Development Center 
feedlot in Ithica, NE.   
Heifers were allowed a 3 week acclimation period while being maintained in the feedlot. 
During this time, heifers were haltered and adapted to being restrained in a tie stall environment 
and exposed to human interaction.  After the 3 week acclimation period, heifers were randomly 
assigned to one of the two treatment groups: 1) control (CON; n=10): fed a finishing diet without 
ZH (Table 1.); and 2) zilpaterol hydrochloride (ZH; n=10): fed the same finishing diet as the 
controls except supplemented with ZH (Zilmax
®
; Merck Animal Health) at 8.33 mg/kg BW on a 
DM basis. For the supplementation of ZH, five percent of the high- moisture corn in the diet was 
replaced with 4.9853% fine ground corn and ZH at 0.0147% calculated to supply ZH at 8.33 
mg/kg of BW on a DM basis.  To ensure similarity between the two diets, five percent of the 
CON diet was replaced with fine ground corn.  Heifers were fed once daily at 0800 h for 20 
days. Prior to feeding, all supplements were individually mixed into each heifer’s daily 
allotment. After 20 days the ZH was withdrawn from the diet for 3 days and the five percent 
high- moisture corn was returned to both diets to replace the five percent ground corn 
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supplement.  The study was designed to follow approved industry procedures and feed ZH for 20 
days followed by a 3 day mandatory withdrawal prior to being shipped to an abattoir.   
 Eight days prior to the beginning of ZH supplementation, heifers were relocated from the 
feedlot to the University of Nebraska-Lincoln Agricultural Research and Development Center 
Nutrition Dairy Barn in Ithica, NE.  The barn had individual stalls that were equipped with 
individual bunks, automatic waterers, and a dairy mattress underneath.  Prior to the heifers being 
moved into the barn, the first ten stalls on each side of the alleyway were randomly assigned to a 
treatment, but were blocked by treatment group (two heifers per block) to ensure that no CON 
shared a water with a ZH heifer.  The heifers were maintained in individual tie stalls which were 
1.34 meters wide by 1.84 meters long for the duration of the trial.  To help with cleanliness, pine 
shavings were added on top of the dairy mattress and replaced as needed.   
Environmental temperature and relative humidity data were collected from inside the 
barn by four HONO U23 Pro v2 temperature/relative humidity data loggers (U23, Onset, 
Bourne, MA, USA). All data from the probes were averaged and compiled to provide an overall 
environmental temperature and relative humidity.  During the trial, the average environmental 
temperature was 9.4º C ± 2.9ºC and the average relative humidity was 57.7% ± 5.2%. In 
addition, the average temperature humidity index was 20.7 ± 2.3 in the barn. 
Catheterization Process 
 Each heifer was fitted with an indwelling jugular catheter (Burdick Sanchez et al., 2013) 
24 hours prior to the start of each blood collection period (d -3, 12, and 20 of the trial).  To insert 
the indwelling jugular catheters, heifers were restrained in a working squeeze chute.  Before 
making the incision, Lidocaine Hydrochloride Jelly USP (Akorn, Inc., Lake Forest, IL, USA) 
was administered directly on the incision site. An incision roughly 2-3 cm long was made in the 
32 
 
skin for more accessibility of the jugular vein.  The indwelling jugular catheters consisted of 
30.48 cm of sterile Tygon® tubing (AAQ04133; US Plastics, Lima, OH, USA; 1.27 mm i.d. and 
2.286 mm o.d.). The tubing was inserted into the jugular vein via a 14-gauge by 5.08-cm thin-
walled stainless steel biomedical needle (o.d.= 3mm). The catheter was secured using tag cement 
and a 2.08-cm wide porous surgical tape at the incision site.  After the catheter was secured, vet 
wrap (Vetrap™; 3M Animal Care Products, St. Paul, MN, USA) was wrapped around the entire 
neck of each heifer to ensure the catheter was stable in the incision site.  There was a portion of 
the tubing that was not inserted into the heifers that served as an extension of the cannula that 
allowed for easier collection of blood samples (Burdick Sanchez et al., 2013). After being fitted 
with their jugular catheters, the heifers were returned to their respective tie stall.  One animal 
developed a sore underneath the halter and another had a catheter failure on day 13 and 21, 
respectively.   
Sample collection was divided into three very intensive blood collection periods.  The 
first period consisted of 3 days prior to the supplementation of ZH (days -2, - 0) and the four 
days following the beginning of   supplementation (days 1-4).  The second collection period was 
during the middle of ZH supplementation which consisted of days 13 through 16.   The third 
period consisted of three days (days 21-23); which was the three day mandatory withdrawal 
period.  
During the three intensive blood collection periods, 18 mL of blood was collected in 
Sarstedt tubes containing no additive (Sarstedt, Inc., Newton, NC USA) at 4 hour intervals 
(0000, 0400, 0800, 1200, 1600, and 2000 hours) from each heifer daily. The blood samples were 
allowed 30 minutes to clot at room temperature prior to being centrifuged at 1500 x g for 20 
minutes at 4º C.  Once the serum was isolated it was stored at -80º C until analysis. At 0800 and 
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2000 hours, an additional 9 mL of blood was collected for the Large Animal Chemistry Profile 
analysis. These samples were collected, separated, and shipped to the Kansas State Veterinary 
Diagnostic Laboratory.    
 Daily, at 1200 hour, a 3 mL blood sample was collected in EDTA Vacutainer® tubes 
(Fisher Scientific, Pittsburg, PA USA) and were immediately analyzed for complete blood cell 
(CBC) counts utilizing a ProCyte Dx Hematology Analyzer (IDEXX Laboratories, Westbrook, 
ME USA).    
Tissue Collection 
 Beginning on day 25 of the trial, the heifers were harvested at the Loeffel Meat 
Laboratory located at the University of Nebraska-Lincoln. The heifers were randomly assigned 
to be harvested on one of the three harvest days (days 25, 26, and 27 of the trial) and within days, 
harvest order was alternated on the basis of treatment, resulting in extended withdrawal time for 
heifers harvested on different days (4, 5, and 6 d after ZH supplementation). After evisceration, 
samples were obtained from the liver, Longissimus muscle (LM) directly above the 13
th
 rib, and 
the Biceps Femoris (BF) from the outer center of the muscle.  These samples were collected 
within 45 minutes of stunning, flash frozen in liquid nitrogen, and stored at -80º C until vitamin 
E analysis.    
Serum Analysis 
 
 Samples were shipped on dry ice and overnighted to the Kansas State University 
Veterinary Diagnostic Laboratory (Manhattan, KS 66506) for a Large Animal Chemistry Profile 
analysis utilizing laboratory methods that are approved by the American Association of 
Veterinary Laboratory Diagnosticians (Visalia, CA). This profile consisted of serum 
concentrations of glucose (mg/dL), blood urea nitrogen (BUN, mg/dL), creatinine (mg/dL), total 
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protein (g/dL), albumin (g/dL), globulin (g/dL), total calcium (mg/dL), phosphorus (mg/dL), 
sodium (mmol/L), potassium (mmol/L), chloride (mmol/L), bicarbonate (mmol/L), anion gap 
((calculated as ([Na+] + [K+]) – ([CL-] + [HCO3
-
]); mmol/L)), sodium : potassium ratio, creatine 
phosphokinase (CPK, U/L), aspartate transaminase (AT, U/L), alkaline phosphatase (AP, U/L), 
γ- glutamyltransferase (GG, U/L), and sorbitol dehydrogenase (SD, U/L).  
 A second set of serum samples were shipped overnight on dry ice to the Iowa State 
University Veterinary Diagnostic Laboratory (Ames, IA 50011) for analysis of vitamin E 
concentrations. Concentrations of vitamin E were determined by a high performance liquid 
chromatography (HPLC) with UV detection set at 292 nm. In summary, 0.5 mL of serum was 
pipetted into 15 mL screw top tubes and is then spiked by adding 100 μL of 0.02 µg/µL Vitamin 
E acetate standard for a 2 ppm spike. Next, 2 mL of 95% ethanol was added to each tube and 
vortexed.  For extraction of Vitamin E, 4 mL of 95/5 hexane/chloroform was added to each tube. 
Tubes were centrifuged for 5 minutes at 1500 rpm.  Once centrifuged, 2mL of the top solvent 
layer (the 95/5 layer) was removed and concentrated in order for analysis by HPLC using UV at 
292 nm.  Vitamin E concentrations were reported as ppm and the detection limit for vitamin E is 
0.5 ppm.   
Serum cortisol concentrations were determined by utilizing the DetectX® cortisol 
immunoassay kit (Arbor Assays, Ann Arbor, MI) in duplicate samples. This kit measures total 
cortisol and the cortisol standard is provided to generate a standard curve. In a 96-well plate, 50 
µL of samples or standards were pipetted into each well. Next, 75 µL of assay buffer was placed 
into the non-specific binding (NSB) wells and 50 µL of assay buffer was pipetted into wells to 
act as a maximum binding well. Next, 25 µL of the cortisol conjugate was added to each well 
followed by adding 25 µL of cortisol antibody to each well, except for the NSB wells. Plates 
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were placed on a plate shaker for 1 hr and afterwards were washed 4 times with 300 µL of wash 
buffer. Next, 100 µL of the TMB substrate was added to each well and allowed to incubate at 
room temperature for 30 minutes before 50 µL of stop solution was added. Then plates were read 
using a plate reader at 450 nm. The minimum detectable concentration was 45.4 ng/mL and the 
intra- and inter- assay coefficients of variation were 18.6% and 16.0%, respectively. To 
determine the serum concentration of cortisol, the unknown samples were compared to a 
standard curve of known cortisol concentrations.  Cortisol concentrations were recorded as 
ng/mL. 
 Insulin concentrations in the serum were determined in duplicate samples by utilizing a 
bovine-specific insulin ELISA according to the manufacturer’s instructions (Cat # 80-INSBO-
E01; Alpco Diagnostics, Salem, NH).  The minimum detectable concentration of insulin was 0.1 
ng/mL and the intra- and inter-assay coefficients of variation were 11.8% and 17.9%, 
respectively.  Concentrations of insulin were recorded as ng/mL.  
 Serum concentrations of lactate were determined by using duplicate samples in a 96-well 
plate format and by utilizing the lactate assay kit (MAK064; Sigma-Aldrich, St. Louis, MO, 
USA).  In summary, plates were incubated at 37º C for 30 minutes followed by using a plate 
reader set at 570 nm to record the results.  To determine the concentration of lactate, unknown 
samples were compared to a standard curve of known lactate concentrations. Lactate 
concentrations were recorded as ng/µL.  
 Concentrations of serum lactate dehydrogenase were determined by utilizing a lactate 
dehydrogenase activity assay kit (MAK066; Sigma-Aldrich, St. Louis, MO, USA) in duplicate 
samples in a 96-well plate format.  Each plate was incubated for 37ºC for 2 minutes followed by 
using a plate reader set at 450 nm to record the initial reading. Plate readings were taken every 3 
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minutes after the initial reading at 450 nm until the most active unknown sample was greater 
than the highest standard.  The final measurement that was utilized for calculating the enzyme 
activity was the value before the most active sample that is near or exceeds the end of the linear 
range of the standard curve.  To determine the lactate dehydrogenase concentrations, the 
unknown samples were compared to a standard curve of known concentrations. Results were 
recorded in milliunits/mL.   
 Serum concentrations of β-hydroxybutyrate were determined by utilizing a β-
hydroxybutyrate assay kit (MAK041; Sigma-Aldrich, St. Louis, MO, USA) in duplicate samples 
in a 96-well plate format.  Each plate was incubated for 37ºC for 30 minutes followed by using a 
plate reader set 450 nm. To determine serum β-hydroxybutyrate concentrations, the unknown 
sample was compared to a standard curve of known β-hydroxybutyrate concentrations and 
results were recorded in ng/µL.  
Tissue Analysis  
 Liver, LM and BF samples were sent overnight on dry ice to the Iowa State University 
Veterinary Diagnostic Laboratory for analysis of vitamin E concentrations in the tissue samples.   
In summary, two 5 g samples of tissue (liver, LM or BF) were weighed for vitamin E analysis 
and placed into 50 mL screw top tubes with Teflon™ lined screw caps.  Samples were spiked 
with 5 ppm vitamin E.  Next, 1 g of Celite™ was added to each tube and vortexed until 
homogenized.  Then 10 mL of 95% ethanol followed by 20 mL of 95/5 hexane/chloroform were 
added to each tube.  After fully mixing, 5mL of the top solvent layer was removed and 
concentrated.  Concentrated samples were analyzed by HPLC using UV set at 292 nm.   Data 
were recorded as ppm.  
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Statistical Analysis  
 Data were analyzed using the MIXED procedure of SAS specific for repeated measures 
(SAS Inst. Inc., Cary, NC USA).  The model included the fixed effects of treatment, time, and 
treatment x time interaction. Each heifer within the treatment was included as the experimental 
unit.  If there was a significant difference in treatment or the treatment x time interaction, data 
were further analyzed separately in the three bleeding periods: baseline (days -2 to 4), middle of 
supplementation (days 13 to 16), and the withdrawal period (days 21 to 23). This was used to 
analyze all the serum metabolites.   
For tissue samples, data were analyzed with treatment included as the fixed effect and 
heifer within treatment was the experimental unit. Specific treatment comparisons were made 
using the PDIFF option in SAS, with P ≤ 0.05 considered significant and 0.05 ≤ P ≤ 0.10 were 
considered a tendency.  All data are reported as LSM±SEM. 
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Table 1.  Composition of finishing diets fed to finishing heifers as a percent of DM basis 
  Treatment 
Item  Control ZH 
Ingredient (%)    
High Moisture Corn  51.00 51.00 
Sweet Bran®  40.00 40.00 
Wheat Straw    5.00   5.00 
Fine Ground Corn        1.8710       1.8710 
Limestone        1.6400       1.6400 
Salt        0.3000       0.3000 
Tallow        0.1000       0.1000 
Beef Trace Mineral        0.0500       0.0500 
Rumensin-90        0.0150       0.0150 
Vitamin A-D-E        0.0165       0.0165 
Tylan-40        0.0075       0.0075 
Supplement
1    
   Fine Ground Corn  5.0       4.9853 
   Zilpaterol Hydrochloride       -       0.0147 
1
The control supplement contained fine ground corn only. The zilpaterol hydrochloride (ZH) 
supplement contained (DM basis) 0.0147% Zilmax
®
 (Merck Animal Health) Type A medicated 
article and 4.9853% fine ground corn and supplied zilpaterol hydrochloride (ZH) 
supplementation (8.33 mg/kg on a DM basis). 
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ABSTRACT: The objective of this study was to evaluate hematological and serum biochemical 
profiles associated with supplementation of zilpaterol hydrochloride (ZH) to feedlot heifers. 
Heifers (n=20; 556±7 kg BW) were randomly assigned to one of two treatment groups: 1) 
Control (CON: no ZH supplementation), or 2) Zilpaterol (ZH: supplemented ZH at 8.33 mg/kg 
per feed on a DM basis). Heifers in the ZH treatment group were supplemented with ZH for 20 
d, followed by a 3 d withdrawal period. The trial was conducted over a 25 d period (-2 to 23 d, 
ZH supplementation beginning on d 1), with three serial blood collection periods: -2 to 4 d, 13 to 
16 d, and 20 to 23 d (withdrawal period).   Blood samples were collected and serum was 
separated then stored at -80ºC until analyzed for serum biochemical profile. Each d, at 1200 h a 
whole blood sample was collected in 4- mL tubes for hematological analysis.  Heifers were 
harvested and tissue samples were collected from the liver, longissimus muscle (LM), and biceps 
femoris (BF) for analysis of vitamin E. There was a treatment effect for serum concentrations of 
calcium (P = 0.008) with concentrations being greater in CON heifers than when compared with 
ZH. A treatment effect was observed for serum concentrations of bicarbonate (P = 0.03), with 
ZH having greater concentrations than CON heifers. A treatment x time interaction was observed 
for glucose (P = 0.02), BUN (P < 0.001), Cl (P = 0.04), CREAT (P ≤ 0.001), and CK (P≤ 
0.001). Overall CREAT, CK, and Cl serum concentrations were greater in ZH compared to CON 
group whereas glucose and BUN concentrations were decreased in the ZH treated heifers.  There 
were no differences in the liver enzymes aspartate transaminase (AST; P = 0.08) and sorbitol 
dehydrogenase (SBD; P = 0.46), however; there was a treatment x time interaction for alkaline 
phosphatase (ALP; P < 0.001) and γ-glutamyltransferase (GGT; P = 0.004). Overall, 
concentrations of ALP were increased in CON compared to ZH heifers. Overall, GGT 
concentrations were greater in ZH treated heifers. In the CBC, there was an overall treatment 
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effect (P = 0.02) for hematocrit, where ZH had increased hematocrit when compared to the CON 
heifers. There was no differences in vitamin E concentrations in the liver (P = 0.28), LM (P = 
0.44), and BF (P = 0.44). These data suggest that in this controlled environment, ZH 
supplementation did result in alterations of the serum biochemical and hematological profiles, 
primarily in variables associated with alterations in protein accretion x(increased CREAT and 
CK along with decreased BUN). However, alteration in serum biochemical and hematological 
profiles observed within the constraints of this study do not appear to have a significant impact 
on the well-being of feedlot heifers.    
Keywords: complete blood cell count, serum profile, β-agonist, cattle 
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INTRODUCTION 
Zilpaterol hydrochloride (ZH; Zilmax
®
, Merck Animal Health, Summit, NJ) is a β2-
adrenergic receptor agonist (β-AA) that has been utilized in the US beef since 2007 (Schmidt and 
Olsen, 2007). The use of ZH has been reported to increase ADG (Montgomery et al., 2009) 
while decreasing DMI, resulting in an overall increase in feed efficiency (Mersmann, 1998; 
Avendaño-Reyes et al., 2006). Furthermore, supplementation of ZH has been reported to 
increase lean muscle mass and decrease adipose deposition. As a β-AA, ZH is binds to 7-
transmembrane G-protein-coupled receptors (Mersmann, 1998). These receptors are part of a 
large family of G-coupled protein receptors that elicit a response by binding to Gs proteins.  
Once coupled with a Gs protein, the enzyme adenylate cyclase is activated to cause cyclic 
adenosine monophosphate (cAMP) to be synthesized (Mersmann, 1998). The synthesized cAMP 
is responsible for the regulation of the catalytic subunit protein kinase A (PKA).  Protein kinase 
A is responsible for many biological effects as it results in the phosphorylation of key enzymes 
(Mersmann, 1998).   
In 2013, it was suggested that there was an association between ZH supplementation and 
reports of slow moving and lame cattle upon arrival at the abattoirs (Thomson et al., 2015). 
Furthermore, Longeragan et al. (2014) reported a suggested association related to ZH 
supplementation and increased cumulative incidence (risk) and incidence of rate of death in 
feedlot cattle. Further, it has been hypothesized that a novel fatigue syndrome in finished cattle 
could be related to ZH supplementation (Thomson et al., 2015). With these reports of suggested 
associations to ZH supplementation, the objective of this study was to conduct an intensive and 
controlled trial to evaluate alterations in the hematological and serum biochemical profiles of 
feedlot cattle supplemented ZH.       
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MATERIALS AND METHODS 
Experimental Design 
All the experimental procedures were approved by the Institutional Animal Care and Use 
Committee at the University of Nebraska (IACUC#902) and were in compliance with the Guide 
for the Care and Use of Agricultural Animals in Research and Teaching. 
Twenty English- influenced crossbred yearling ovariectomized heifers (556± 7 kg initial 
BW) from the University of Nebraska Agricultural Research and Development Center (Ithica, 
NE) feedlot were utilized for the study. While being maintained in the feedlot, heifers were 
acclimated to being halter tied and exposed to frequent human interaction to allow the heifers to 
acclimate to the environment more efficiently and reduce stress when placed into the tie stall 
barn during the study. This acclimation period occurred 3 wk prior to the start of the study.    
At the conclusion of the adaptation period, heifers were randomly assigned to one of two 
treatment groups (n=10 per treatment): 1) Control (CON): heifers received a finishing diet with 
no ZH supplementation (Table 1); 2) zilpaterol hydrochloride (ZIL): heifers received a finishing 
diet with ZH (Zilmax
®
, Merck Animal Health) supplementation at a 8.33 mg/kg BW on a DM 
basis. For delivery of ZH, 5% of the high-moisture corn in the finishing diet was replaced with 
4.9853% fine-ground corn containing ZH at 0.0147%. For the CON diet, 5% of the high-
moisture corn was replaced with fine ground corn to ensure similarity between to two diets.   
Supplements were individually mixed into each heifer’s daily allotment prior to feeding. Heifers 
were fed once daily at 0800 for the entire 26 d feeding period, including the 3 d withdraw period.  
On day 20, the 5% high-moisture corn was returned to the diet of all heifers (ZH and Controls) 
for the required 3 d mandatory withdrawal period to replace the 5% ground corn supplement. 
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The design of the trial followed common industry feeding practices for feeding ZH for the 20 d 
period followed by the 3 d mandatory withdrawal before heifers would be shipped to the abattoir.  
Eight d prior to the start of the trial, the heifers were transported to the University of 
Nebraska Agricultural Research and Development Center Nutrition Barn (Ithica, NE).  The 
Nutrition Barn was equipped with individual bunks, automatic waters, and dairy mattresses. 
Prior to heifers being relocated into the barn, each heifer were blocked by treatment groups to tie 
stalls (two heifers per block) to ensure that no CON heifer shared a waterer with a ZH heifer. 
Location of blocks within the tie stall barn was randomly assigned.  For the duration of the trial, 
heifers where maintained in their individual tie stalls.  
Due to the duration of the study (25 d), blood collection was separated into three 
collection periods: serum collection period1 (SCP1; d -2 thru 4 d post ZH supplementation), 
serum collection period 2 (SCP2; d 13 – 16), and serum collection period 3 (SCP3; d 21 – 23). 
Twenty- four h prior to the start of each serum collection period, heifers were fitted with an 
indwelling jugular catheter (Burdick Sanchez et al., 2013). For the jugular catheterization, heifers 
were placed in a restraining chute for 5 to 10 min. A 2–3 cm incision was made into the skin 
above the jugular vein for easier access. Catheters consisted of 30.48 cm of sterile Tygon
® 
tubing 
(AAQ4113; US Plastics, Lima, OH, USA; 1.27 mm i.d. and 2.286 mm o.d.) and were inserted 
into the jugular vein using a 14- gauge by 5.08-cm thin- walled stainless steel biomedical needle 
(o.d. =3 mm). Stabilization of the catheter was achieved by using tag cement and a 2.08-cm wide 
porous surgical tape around the incision site. The entire neck region of each heifer was wrapped 
with vet wrap (Ventrap™; 3 M Animal Care Products, St. Paul, MN, USA) to that the catheter 
injection site was stable. The remaining portion of the tubing not inserted into the jugular served 
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as the extension portion of the cannula that was utilized for collection of the blood samples 
(Burdick Sanchez et al., 2013).  
Environmental temperature and relative humidity data were collected from inside the 
barn by four HONO U23 Pro v2 temperature/relative humidity data loggers (U23, Onset, 
Bourne, MA, USA). All data from the loggers were averaged and compiled to provide an overall 
environmental temperature and relative humidity.  During the trial, the average environmental 
temperature was 9.4º C ± 2.9ºC and the average relative humidity was 57.7% ± 5.2%. In 
addition, the average temperature humidity index was 20.7 ± 2.3 in the barn. 
For each day of SCP1, SCP2, and SCP3, 18mL of blood was collected at 0800 and 2000 
h in Sarstedt tubes containing no additive (Sarstedt, Inc., Newton, NC USA) for serum analysis.  
All blood samples were allowed to clot for 30 min at room temperature prior to being centrifuged 
at 1500 x g for 20 min at 4
o
C. The isolated serum samples were stored at -80
o
C until analysis. An 
additional 4 mL blood sample was collected in 4- mL Vacutainers
®
 containing EDTA (Fisher 
Scientific, Pittsburg, PA USA) at 1200 h and immediately analyzed for complete blood cell 
(CBC) counts using a ProCyte Dx Hematology Analyzer (IDEXX Laboratories, Westbrook, ME 
USA).    
At the conclusion of the study, heifers were transported (58 km) to the Loeffel Meat 
Laboratory located at the University of Nebraska – Lincoln and harvested.  Due to limitations to 
the capacity of the Loeffel Meat Laboratory, heifers were harvested of a 3 d period (25, 26, and 
27 d). Heifers were randomly assigned to one of the three harvest d, with an equal number of 
heifers from each treatment group harvested on each day.  Order of harvest was also alternated, 
within days on the basis of treatment. After evisceration, tissue samples were collected from the 
LM (directly above the 13
th
 rib, 3/4
th
 the lateral length of the LM), biceps femoris (BF; outer 
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center of the muscle) and liver.  Tissue samples were collected and immediately flash frozen in 
liquid nitrogen and stored at -80
 o
C until analyzed for vitamin E.  
Two heifers from the ZH treatment group were removed during the trial. One heifer 
developed an abrasion underneath the halter and one heifer due to loss of patency of jugular 
catheter on d 13 and 21. This resulted in 10 heifers in the CON treatment and 8 heifers in the ZH 
treatment group. 
Serum Analysis 
Serum samples were shipped overnight on dry ice to the Kansas State Veterinary 
Diagnostic Laboratory (Manhattan, KS 66506) for a Large Animal Chemistry Profile. The Large 
Animal Chemistry Profile analyzed glucose (mg/dL), blood urea nitrogen (BUN, mg/dL), 
creatinine (mg/dL), total protein (g/dL), albumin (g/dL), globulin (g/dL), total calcium (mg/dL), 
phosphorus (mg/dL), sodium (mmol/L), potassium (mmol/L), chloride (mmol/L), bicarbonate 
(mmol/L), anion gap (mmol/L), Na:K Ratio, creatine kinase (CK, U/L),  aspartate transaminase 
(AST, U/L), alkaline phosphatase (ALP, U/L), γ- glutamyltransferase (GGT, U/L), and sorbitol 
dehydrogenase (SBH, U/L) utilizing methods that are approved by the American Association of 
Veterinary Laboratory Diagnosticians (Visalia, CA).  
In addition, serum samples were shipped overnight on dry ice to the Iowa State 
University Veterinary Diagnostic Laboratory (Ames, IA 50011) for Vitamin E concentration 
analysis. Vitamin E concentrations were determined by a high performance liquid 
chromatography (HPLC) with UV detection test. Briefly, 0.5 mL of serum was pipetted into 15 
mL screw top tubes and was then spiked by adding 100 µL of 0.02 µg/µL Vitamin E acetate 
standard for a 2 ppm spike. Then 2 mL of 95% ethanol to each tube was added and vortexed. For 
the extraction of Vitamin E, 4 mL of 95/5 hexane/chloroform was added to each tube. Tubes 
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were centrifuged for 5 min at 1500 rpm. Then 2 mL of the top solvent layer (the 95/5 layer) was 
removed and concentrated in order for analysis by HPLC using UV at 292 nm. Concentrations of 
Vitamin E were recorded as ppm. The detection limit for Vitamin E is 0.5 ppm. 
Cortisol concentrations were determined by the DetectX® cortisol immunoassay kit 
(Arbor Assays, Ann Arbor, MI) in duplicate samples, according to the manufacturer’s 
instructions. Cortisol concentrations in the samples were determined by comparison to a standard 
curve of known cortisol concentrations. In a 96-well plate, 50 µL of samples or standards were 
pipetted into each well. Next, 75 µL of assay buffer was placed into the non-specific binding 
(NSB) wells and 50 µL of assay buffer was pipetted into wells to act as a maximum binding 
well. Next, 25 µL of the cortisol conjugate was added to each well followed by adding 25 µL of 
cortisol antibody to each well, except for the NSB wells. Plates were placed on a plate shaker for 
1 h and afterwards were washed 4 times with 300 µL of wash buffer. Next, 100 µL of the TMB 
substrate was added to each well and allowed to incubate at room temperature for 30 minutes 
before 50 µL of stop solution was added. Then plates were read using a plate reader at 450 nm.   
The minimum detectable concentration of cortisol was 45.4 ng/mL and the intra- inter- assay 
coefficients of variation were 18.6% and 16.0%, respectively. Cortisol concentrations were 
recorded as ng/mL.  
Insulin concentrations were determined by utilizing a bovine-specific insulin ELISA 
according to the manufacturer’s instructions (Cat # 80-INSBO-E01; Alpco Diagnostics, Salem, 
NH). The minimum detectable concentration of insulin was 0.1 ng/mL and the intra- and inter-
assay coefficients of variation were 11.8% and 17.9%, respectfully. Concentrations of insulin 
were recorded as ng/mL.  
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Serum lactate concentrations in the serum were determined in duplicate samples utilizing 
a lactate assay kit according to the manufacturer’s instructions (MAK064; Sigma-Aldrich, St. 
Louis, MO, USA).  To determine the concentration of lactate, unknown samples were compared 
to a standard curve. Concentrations of lactate were recorded as ng/µL.  
 Serum lactate dehydrogenase (LDH) were determined in duplicate samples by utilizing a 
LDH activity assay kit (MAK066; Sigma-Aldrich, St. Louis, MO, USA).  Plates were incubated 
for 37º C for 2 minutes followed by using a plate reader set at 450 nm to record the initial 
absorbance. After the initial reading, subsequent absorbances were measured every 3 min at 450 
nm until the most active unknown sample was greater than the highest standard. The final 
measurement utilized in calculating the enzyme activity was the penultimate reading or the value 
before the most active sample is near or exceeds the end of the linear range for the standard 
curve. To determine the concentration of LDH, the unknown samples were compared to a 
standard curve of known concentrations. Concentrations of LDH were recorded as milliunits/mL.  
Serum concentrations of β-hydroxybutyrate were determined by utilizing a β-
hydroxybutyrate assay kit according to the manufacturer’s instructions (MAK041; Sigma-
Aldrich, St. Louis, MO, USA) in duplicate samples. To determine β-hydroxybutyrate 
concentrations, the unknown sample was compared to a standard curve of known β-
hydroxybutyrate concentrations and results were recorded in ng/μL.  
Tissue Analysis  
Liver, LM, and BF samples were shipped overnight while on dry ice to Iowa State 
University’s Veterinary Diagnostic Laboratory (Ames, IA 50011) for analysis of vitamin E 
concentrations, as described above.    
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Statistical Analysis 
 Data were analyzed using the MIXED procedure of SAS specific for repeated measures 
(SAS Inst. Inc., Cary, NC). The model included treatment, time, and treatment x time interaction 
for the fixed effects.  Heifer within treatment was included as the experimental unit. If there was 
a significant difference in treatment or the treatment x time interaction, data were further 
analyzed separately in the three blood collection periods: d -2 to 4 (baseline, supplementation 
starting on 0 d), d 13 to 16 (middle of supplementation), and d 21 to 23 (mandatory withdrawal 
period).  
 For tissue samples, data were analyzed with treatment included as the fixed effect and 
heifer within treatment was the experimental unit. Specific treatment comparisons were made 
using the PDIFF option in SAS, with P ≤ 0.05 considered significant and 0.05 ≤ P ≤ 0.10 were 
considered a tendency.  All data are reported as least square means ± SEM.  
RESULTS 
Serum Metabolites 
 When data from the large animal chemistry profile were initially analyzed in separate 
0800 and 2000 h, glucose was the only variable that was significantly different in the 0800 h 
from the 2000 h. Therefore, glucose was analyzed into separate 0800 and 2000 h samples. All 
other variables were analyzed with 0800 and 2000 h together.  For 0800 h, there was no 
treatment x time interaction (P = 0.68) or treatment effect (P = 0.46), however, there was an 
overall time effect (P ≤ 0.001; Figure 1A). For 2000 h, there was no overall treatment x time 
interaction (P = 0.30). There was a treatment (P = 0.0018) and a time (P ≤ 0.001) effect for 2000 
h serum concentrations of glucose (Figure 1B). Glucose concentrations were decreased in ZH 
heifers compared to the CON (74.9 ± 1.35 mg/dL vs 81.9 ± 1.34 mg/dL, respectively)   Glucose 
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was further analyzed into the 3 collection periods. There was a treatment (P ≤ 0.04) and time (P 
≤ 0.004) effects observed in all 3 collection periods at 2000 h.  
 For serum BUN concentrations, an overall treatment x time interaction (P < 0.001) was 
observed (Figure 2). When further analyzed as the 3 collection periods there was a treatment x 
time interaction observed in period 1 (P = 0.05) and period 2 (P = 0.002), but not in period 3 (P 
= 0.53).  After initiation of supplementation on d 0 in period 1, BUN concentrations were greater 
in CON than ZH heifers at h 36. During period 2, BUN concentrations were greater in CON 
heifers compared with ZH heifers at each time point. Serum BUN concentrations were affected 
by treatment (P = 0.01) in the final collection period. Specifically, BUN concentrations were 
greater in CON when compared with ZH heifers (12.8 ± 0.67 mg/dL vs 10.0 ± 0.74 mg/dL, 
respectfully).   
 A treatment x time interaction (P ≤ 0.001) was observed for serum concentrations of 
creatinine (Figure 3). However, there were no treatment x time interactions when each collection 
period was analyzed independently (period 1: P = 0.58, period 2: P = 0.69, period 3: P = 0.65).  
Serum creatinine concentrations were affected by treatment in period 2 (P = 0.001) and period 3 
(P = 0.003). Specifically, serum creatinine concentrations were greater in ZH compared with 
CON heifers (period 2: 1.4 ± 0.06 mg/dL vs 1.07 ± 0.06 mg/dL; period 3: 1.5 ± 0.07 mg/dL vs 
1.1 ± 0.07 mg/dL, respectfully). In conjunction with the treatment effect, there was a time effect 
for each collection period (P ≤ 0.02). For serum concentrations of CK, a treatment x time 
interaction (P ≤ 0.001) was observed. When analyzed within the 3 collection periods, there was 
no treatment x time interaction (P = 0.28) for period 1, while there were a treatment x time 
interactions in period 2 (P ≤ 0.001) and period 3 (P = 0.002; Figure 4). Concentrations of CK 
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remained greater in ZH treated heifers in both periods 2 (305.8 ± 30.6 U/L vs 135.9 ± 29.5 U/L) 
and 3 (331.6 ± 36.2 U/L vs 169.9 ± 32.4 U/L).   
 There were no overall treatment effects (P ≥ 0.39) nor treatment x time interactions (P ≥ 
0.18) for serum concentrations of total protein, albumin, globulin, or anion gap (Table 2). 
However, there was an overall time effect observed for these variables (P ≤ 0.001).   
In regards to mineral concentrations in the serum, there were no overall treatment x time 
interaction for serum concentrations of calcium (P = 0.26) and phosphorus (P = 0.65), but there 
was an overall treatment effect (P = 0.008) and time effect (P ≤ 0.001) for serum calcium 
concentrations (Table 2). Specifically, concentrations of calcium were greater in CON heifers, 
when compared to ZH heifers (9.8 ± 0.07 mg/dL vs 9.5 ± 0.07mg/dL). There was no treatment 
effect for serum concentrations of phosphorus (P = 0.90), however there was a time effect (P ≤ 
0.001).  
There was no overall treatment x time interaction for serum concentrations for potassium 
(P = 0.20) but there was a tendency for sodium (P = 0.07) and Na:K ratio (P = 0.06; Table 2).  
Additionally, there were no treatment effects for serum concentrations of potassium (P = 0.16), 
sodium (P = 0.21) and Na:K ratio (P = 0.11).  However, there was an overall time effect (P ≤ 
0.001) for these variables.  For serum concentrations of chloride, there was an overall treatment x 
time interaction (P = 0.04), however, when looking at the 3 collection periods individually there 
were no treatment x time interactions observed (Figure 5). In collection period 2, there was a 
treatment effect (P = 0.04), with ZH heifers having greater concentrations of serum chloride 
compared with the CON heifers (99.2± 0.5 mmol/dL vs 97.6 ± 0.5 mmol/dL, respectfully). 
There was no treatment x time interaction (P = 0.21), but there were an overall treatment 
(P = 0.03) and time (P ≤ 0.001) effect on serum concentrations of bicarbonate (Table 2). A 
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treatment effect was observed in collection period 2 (P=0.01) and period 3 (P=0.03) of the study. 
Specifically, ZH heifers had greater serum concentrations of bicarbonate compared to the CON 
heifers (period 2: 25.6 ± 0.22 mmol/dL vs 24.7 ± 0.22 mmol/dL; period 3: 25.9 ± 0.32 mmol/dL 
vs 24.9 ± 0.29 mmol/dL, respectfully). 
Four liver enzymes that are routinely evaluated to diagnosis damage of liver cells were 
also analyzed in the complete blood serum profile: aspartate transaminase (AST), alkaline 
phosphatase (ALP), γ- glutamyltransferase (GGT), and sorbitol dehydrogenase (SBH).  There 
was no treatment x time interactions (P ≥ 0.08) or treatment effects (P ≥ 0.64) for the liver 
enzymes AST (P = 0.08) and SBH (P = 0.46); however there were overall time effects (P ≤ 
0.001; Table 2). There was treatment x time interactions observed for the liver enzymes ALP (P 
< 0.001) and GGT (P = 0.004). When looking at the individual collection periods for ALP, 
period 1 had a treatment x time interaction (P < 0.001). Additionally, there were treatment (P = 
0.04) and time (P ≤ 0.001) effects in the final collection period (period 3) in which CON (104.7 
± 6.7 U/L) had greater concentrations of ALP when compared to the ZH heifers (82.5 ± 7.5 U/L; 
Figure 6).  
There was no treatment effect (P = 0.62) or treatment x time interaction (P = 0.20) for 
serum concentrations of insulin, but there was a time effect (P ≤ 0.001).  There was no treatment 
x time interaction (P = 0.75) or treatment effect (P = 0.19) for serum cortisol concentrations. 
However, there was a time effect (P ≤ 0.001) on serum cortisol. There were no treatment x time 
interaction (P ≥ 0.20) or treatment effect (P ≥ 0.14) for serum concentrations of lactate, LDH, 
and β-hydroxybutyrate (Table 2); however, there was an overall time effect (P ≤ 0.001).  
There was no treatment x time interaction (P = 0.26) or treatment effect (P = 0.28) for 
serum concentrations of vitamin E (Table 2). Vitamin E concentrations in the tissue samples can 
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be seen in Table 4. Supplementation of ZH did not affect vitamin E concentrations within the 
liver (P = 0.28), LM (P = 0.44), and the BF (P = 0.44). 
Complete Blood Cell Counts 
 There were no treatment x time interactions for total white blood cells (P = 0.46), red 
blood cells (P = 0.58), hemoglobin (P = 0.69), hematocrit (P = 0.60), platelets (P = 0.90), 
neutrophils (P = 0.96), lymphocytes (P = 0.17), and monocytes (P = 0.66; Table 3). In addition, 
there were no treatment x time interactions for the percentage of neutrophils (P = 0.90), 
lymphocytes (P = 0.63), monocytes (P = 0.33). There was an overall treatment effect (P = 0.02) 
for hematocrit, where the ZH heifers (34.1 ± 0.69) had greater concentrations when compared to 
the CON heifers (31.5 ± 0.68).  
DISCUSSION 
 Currently there is limited information concerning the use of β-AAs and animal 
stress. Over the past couple of years there have been observed mobility issues in cattle at 
abattoirs and this has generated concern in the beef industry. These mobility issues are described 
as the cattle being nonambulatory or fatigued with some appearing to have sloughed hoof walls, 
which have been observed upon arrival at the abattoirs (Thomson et al., 2015).  For all variables 
that were measured there were time effects (P≤ 0.001) observed, however due to the limited 
number of samples analyzed over a 24 h period and diurnal patterns of metabolites it would be 
difficult to describe the pattern in which we see these metabolites change over time. Evaluation 
of time was not the purpose of this study.  The purpose of this study was to evaluate alterations 
in metabolic and complete blood chemistry profiles with supplementation of ZH and observe 
treatment and treatment x time interactions.         
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  In cattle, studies utilizing other β-AAs such as clenbuterol and cimaterol have reported 
differences in protein, lipid, and glucose metabolism (Eisemann et al., 1988). Blood glucose 
concentrations measured when cattle are supplemented with β-AAs have been inconsistent. No 
differences in glucose and insulin concentrations were found during cimaterol supplementation 
of Friesian steers when compared to the control steers (Chikhou et al., 1991). Another study 
observed that whole-blood concentrations of glucose decreased in cattle that were supplemented 
with ZH (Bibber-Krueger et al., 2015). The present study had similar results in which serum 
glucose concentrations were decreased in heifers supplemented with ZH. Similar results were 
observed in finishing steers, where blood glucose concentrations decreased after d 21 of ZH 
supplementation (Van Bibber et al., 2010). It has been suggested that the decrease in glucose 
concentrations are the result of the activation of β-adrenergic receptors that stimulate the 
secretion of red blood cells in the spleen, thus increasing the number of cells available to 
metabolize glucose (Bibber-Krueger et al., 2015).  In regards to insulin, the current study 
observed no significant treatment effects in insulin concentrations throughout the duration of the 
study.  
 When supplementing with β-AAs, the most noticeable alterations in carcass composition 
are in the growth of skeletal muscle. This increase in muscle mass is due to β-AA binding to the 
naturally occurring membrane bound β2-adrenergic receptors that are primarily located on 
skeletal muscle and adipose tissue (Mersmann, 1998). When these β-receptors are activated they 
induce lipolysis and protein accretion (Mersmann, 1998).  In the current study, BUN 
concentrations were decreased in heifers supplemented with ZH, which is indicative of increased 
nitrogen retention. Increased nitrogen retention is a reflection of decreased protein catabolism in 
skeletal muscle (Bibber-Krueger et al., 2015).  The heifers in the current study were provided 
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with adequate nutrition to support any additional lean muscle accretion through the duration of 
the study. The decrease in BUN concentrations is similar to other studies that have utilized 
various β-AAs. When steers were administered clenbuterol, reduced BUN concentrations were 
observed (Ricks et al., 1984). In conjunction, Bibber-Krueger et al. (2015) observed decreased 
plasma urea nitrogen (PUN) in cattle supplemented with ZH when compared to control cattle.  
 In previous cattle studies utilizing clenbuterol, differences in protein metabolism have 
been observed (Eisemann et al., 1988). During normal muscle metabolism, creatinine is a 
product of the breakdown of creatine. Creatinine is generally accepted as a measurement of 
muscle mass.  There is a positive correlation between creatinine concentrations and the increase 
in HCW, DP, and the proportion of lean mass that is observed when administering β-AAs 
(Istasse et al., 1990). The increase in HCW, DP, and lean mass are factors that directly correlate 
to the increase in overall muscle mass. A theory to increases in creatinine production is built 
around the recognition that changes reflect alterations in the size of the creatine pool in the 
normal biological system (Perrone et at., 1992). The alterations in the creatine pool are most 
likely the result in the changes in total muscle mass (Perrone et al., 1992). In agreement with the 
current study, the administration of β-AAs has caused an increase in serum concentrations of 
creatinine (Chikhou et al., 1993; Quirke et al., 1988). With increased concentrations of creatinine 
we would suspect to observed increases in CK concentrations as well. In the current study, 
concentrations of CK were greater in heifers supplemented with ZH starting at h 36 and 
remained greater throughout the remainder of the trial when compared to the control heifers. 
Creatinine phosphokinase is the catalyst for the reaction converting creatine to phosphocreatine 
(in which a by-product is creatinine). As a result it was expected to have greater concentrations 
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of CK present to catalyze this reaction. This increase in CK has been well documented, including 
the FDA approval studies for Zilmax
® 
(FDA, 2006).  
 Evaluation of blood metabolite concentrations in relation to cattle supplemented with ZH 
is very limited. Plasma is composed of 91-92% water and the rest is solids constituents. Plasma 
proteins are the most abundant in these constituents. Albumen and globulin are two major classes 
of proteins that make up total protein in the serum. In feedlot lambs, the supplementation of ZH 
or ractopamine hydrochloride (RH) resulted in no alterations in the overall protein status (López-
Carlos et al., 2010). In another study, Ricks et al. (1984) observed similar results in which there 
were no significant alterations in albumin and total protein in steers administered clenbuterol. 
Relative to this study, there were no significant alterations in albumin, globulin and overall total 
serum protein.  
 The evaluation of mineral concentrations in serum of cattle supplemented with ZH is 
limited. Ricks et al. (1984) observed no obvious abnormalities with calcium and phosphorus 
concentrations in steers administered clenbuterol. Similarly in this study, there were no 
significant differences in phosphorus concentrations; however, there was a treatment difference 
for concentrations of serum calcium. Concentrations of calcium in the serum were lower (P = 
0.008) in cattle supplemented ZH.  However, the circulating pool of serum concentrations of 
minerals could be an unreliable measurement on the total body mineral status of an animal due to 
the significant amount that is stored in bone (Russel and Roussel, 2007).  
 The electrolyte sodium is a major cation that maintains the volume of the extracellular 
fluid and the serum concentration of sodium is representative of the total body sodium due to this 
cation being essentially confined to the extracellular fluid (Russel and Roussel, 2007).  No 
differences for serum concentrations of sodium were expected in the current study as all heifers 
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had ab libitum access to water. The current study revealed tendencies for a treatment x time 
interaction for sodium (P = 0.07) and Na:K ratio (P = 0.06). A major anion in the extracellular 
fluid is chloride and alterations in serum chloride tend to resemble sodium due to the combined 
renal reabsorption of sodium and chloride (Russell and Roussell, 2007).   
    Serum concentrations of bicarbonate were lower in CON heifers when compared to ZH 
in the present study, however, both treatment groups were within the normal biological reference 
range of 17-29 mmol/L for cattle (Kaneko et al., 2008). Bicarbonate concentrations are a 
reflection of the acid-base status of the animal and are related to the total carbon dioxide 
concentrations (Russell and Roussel, 2007). Eisemann and Huntington (1987) reported that 
clenbuterol supplemented to cattle resulted in an increase in blood flow and oxygen uptake in the 
hind-quarters. The greater bicarbonate concentrations observed in ZH heifers could suggest an 
increase in the oxygen that is available due to the increase respiration rate observed with 
supplementation of a β2-AA.  
 The enzymes ALP, AST, GGT and SBH are a component of clinical chemistry profiles 
for cattle as they are indicative of damage or injury to the liver. The relationship between these 
liver enzymes and β-AA supplementation is not well documented. In the current study there were 
no treatment x time interactions for serum concentrations of SBH or AST. A previous study 
observed elevated concentrations of AST in Friesian steers supplemented with cimaterol, 
however, the concentration of AST was still within the range of normal healthy cattle (Chikhou 
et al., 1993).   There were  treatment x time interactions observed for ALP and GGT.  Normal 
reference values in cattle for ALP concentrations are 78-132 U/L (Kaneko et al., 2008). Ricks et 
al. (1984) reported no abnormalities in the liver enzyme ALP in Hereford steers administered 
clenbuterol. Even though there were alterations in some liver enzyme concentrations in both 
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previous and current studies, the concentrations of these enzymes were within the biological 
range for healthy cattle.  
 During times of stress, serum cortisol concentrations increase to help the body respond to 
the stressor by stimulating cells to produce glucose or alternative forms of energy and to increase 
blood flow to distribute glucose and other nutrients to cells as fast as possible (Reece et al., 
2015). In the current study, serum concentrations of cortisol were not different between 
treatment groups. Other studies have reported similar results in different species supplemented 
with β-AAs (Marchant- Forde et al., 2003; Li et al., 2000). Brukmaier et al. (1992) conducted 
research on the responses of calves to exercise (stress) during the feeding of clenbuterol and the 
serum concentrations of cortisol were not different between treatment groups. Thus, serum 
cortisol does not appear to be influenced by ZH supplementation.  
 The ketone body β-hydroxybutyrate is produced in the liver by metabolism of non-
essential fatty acids and elevated concentrations are indicative of a negative energy balance 
(Ospina et al., 2010). In the current study, no difference was observed between treatment groups 
for β-hydroxybutyrate. Eisemann et al. (1988) reported no differences in β-hydroxybutyrate 
concentrations in steers supplemented with clenbuterol. In addition, Bibber-Krueger et al. (2015) 
observed no difference in β-hydroxybutyrate concentrations for steers supplemented with ZH.  
These observations could suggest that β-hydroxybutyrate is being metabolized efficiently enough 
to avoid being accumulating in the blood (Bibber-Krueger et al., 2015).  When cells have a high 
demand for glucose, lactate is produced by the oxidation of NADH by pyruvate to encourage the 
continuation of glycolysis to occur (Reece et al., 2015). In the current study, there were no 
observed differences for serum concentrations of lactate. Previous studies have reported similar 
results with the supplementation of ZH (Bibber-Krueger et al., 2015; Thomson et al., 2015). 
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Bibber-Krueger et al. (2015) observed that as days on ZH supplementation increased, the 
concentrations of lactate numerically decreased. However, the aforementioned study did not 
include a withdrawal period as in the current study. Previous studies have reported increases in 
lactate concentrations. Eisemann et al. (1988) observed an increase in lactate concentrations 
when steers were administered clenbuterol. Another study incorporated P-5369 and Q-2636 into 
milk replacer for calves and reported similar findings where lactate increased in the β-AA treated 
group. Differences between this study and others could be explained by measuring during the 3 d 
withdrawal period only whereas other studies measured during supplementation of the β-AA. 
Lactate dehydrogenase (LDH) is the glycolytic enzyme that is released into plasma as a result of 
muscle injury or necrosis (Russell and Roussel, 2007). The biological reference range in healthy 
cattle for LDH concentrations is 692-1445 U/ L (Kaneko et al., 2008).  There was no difference 
in serum concentrations of LDH in the current study.  A case study in horses administered ZH 
observed increased concentrations of LDH (Wagner et al., 2008).  This observation could 
possibly be explained by differences in species since administration of ZH is not approved to be 
utilized in horses. Vitamin E is contained in cell membranes and acts as the last line of defense 
towards lipid oxidation of the membranes (Kaneko et al., 2008). The presence of vitamin E 
allows cells to replace damaged membrane lipids via normal cell turnover. In the current study, 
no differences were observed in the serum concentrations of vitamin E in both the serum and the 
tissue samples. To the knowledge of the authors of the current manuscript, there are no known 
data on the effect of β-AA’s on concentrations of vitamin E.  
 Evaluation of complete blood cell count (CBC) was measured throughout the duration of 
the study. Complete blood cell count is used to assess the overall health of the animal and can 
suggest a potential illness when physical examinations results are vague (Jones and Allison, 
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2007). No significant differences were observed in the variables included in the CBC except for 
hematocrit. In the current study, ZH heifers had greater hematocrit when compared to CON 
heifers. Greater packed cell volume or hematocrit values can be the result of dehydration, 
asphyxia, or excitement that causes the release of erythrocytes concentrated in the spleen (Reece 
et al., 2015). While there was a treatment effect on hematocrit, both groups were still well within 
the normal biological range for healthy cattle. The normal reference range for hematocrit is 24-
46% (Jones and Allison, 2007) and the ZH heifers for the current study were 34.1% overall.  
 In conclusion, there were some alterations in serum metabolite concentrations that were 
primarily due to the increase in muscle mass that is associated with the supplementation of β-
AAs. Additionally, there were alterations in serum concentrations of glucose, however, both 
treatment groups were above the normal reference range of cattle. Overall the supplementation of 
ZH had no detrimental effects on the metabolic and blood chemistry of feedlot heifers.    
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Table 1.  Composition of finishing diets fed to control (CON) and zilpaterol (ZH) heifers as a 
percent of DM basis during 20 supplementation with a 3-d withdrawal. 
 
 1
Heifers receiving zilpaterol hydrochloride for 20-d period with 3-d withdrawal 
2
Sweet Bran, (Cargill Corn Milling; Blair, NE) 
3
Elanco Animal Health; Greenfield, IN 
4
The control supplement contained fine ground corn only. Zilpaterol hydrochloride (ZH) 
supplement contained (DM basis) 0.0147% Zilmax
®
 (Merck Animal Health) Type A medicated 
article and 4.9853% fine ground corn and supplied zilpaterol hydrochloride (ZH) 
supplementation (8.33 mg/kg on a DM basis). Supplement was fed for 20 d. 
  Treatment 
Item  Control ZIL 
Ingredient (%)    
High Moisture Corn  51.00 51.00 
Sweet Bran
2 
 40.00 40.00 
Wheat Straw    5.00   5.00 
Fine Ground Corn        1.8710       1.8710 
Limestone        1.6400       1.6400 
Salt        0.3000       0.3000 
Tallow        0.1000       0.1000 
Beef Trace Mineral        0.0500       0.0500 
Rumensin-90
3 
       0.0150       0.0150 
Vitamin A-D-E        0.0165       0.0165 
Tylan-40
3 
       0.0075       0.0075 
Supplement
4    
   Fine Ground Corn  5.0       4.9853 
   Zilpaterol Hydrochloride       -       0.0147 
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Table 4. Effect of zilpaterol hydrochloride (ZH) supplementation (8.33 mg/kg on a DM basis) on 
vitamin E in tissue samples following 20-d ZH supplementation. 
1
Heifers receiving zilpaterol hydrochloride for 20-d period with 3-d withdrawal 
  
 Treatment   
Item CON
 
ZIL
1 
SEM P-value 
Liver 2.56 2.14 0.27 0.28 
Longissimus
 
0.21 0.32 0.09 0.44 
Biceps Femoris
 
0.42 0.32 0.12 0.44 
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Treatment             = 0. 46 
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Treatment x Time = 0.68 
Period 1 
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Time                       = 0.006 
Treatment x Time  = 0. 59 
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Time                      = 0.04 
Treatment x Time  = 0.43 
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Figure 1. Glucose concentrations during the 20 d supplementation and 3 d withdrawal period of 
heifers supplemented with Zilpaterol Hydrochloride (ZH) and control (CON) heifers at (A) 0800 and 
(B) 2000 h 
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 Figure 2. Blood urea nitrogen concentrations during the 20 d supplementation and 3 d withdrawal 
period of heifers supplemented with Zilpaterol Hydrochloride (ZH) and control (CON) heifers ((* 
Treatment x Time interaction (P < 0.05))  
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Figure 3. Creatinine concentrations during the 20 d supplementation and 3 d withdrawal period of 
heifers supplemented with Zilpaterol Hydrochloride (ZH) and control (CON) heifers. 
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Figure 4. Creatine kinase concentrations during the 20 d supplementation and 3 d withdrawal period of heifers 
supplemented with Zilpaterol Hydrochloride (ZH) and control (CON) heifers. ((* Treatment x Time interaction 
(P < 0.05))   
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Figure 5. Chloride concentrations during the 20 d supplementation and 3 d withdrawal period of heifers 
supplemented with Zilpaterol Hydrochloride (ZH) and control (CON) heifers.  
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Figure 6. Alkaline Phosphatase concentrations during the 20 d supplementation and 3 d withdrawal 
period of heifers supplemented with Zilpaterol Hydrochloride (ZH) and control (CON) heifers.  
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Figure 7. γ- Glutamyltransferase concentrations during the 20 d supplementation and 3 d withdrawal 
period of heifers supplemented with Zilpaterol Hydrochloride (ZH) and control (CON) heifers.  
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Suggestions for Future Investigation 
 With any scientific endeavor, further investigation and questions arise based upon the 
results for the study. There are a few other avenues of research that could be pursued in relation 
to the current study. A reason to potentially pursue further investigation would be to gain a better 
understanding of how the responses observed with β2-adrenergic agonists are being achieved in 
the body. Fully understanding the mechanism will give better insight to develop a supplement 
that could be accepted by the industry in the future.   
 If Zilmax
®
 would be accepted again, it would be valuable to look at heat stress in cattle 
supplemented ZH. Ultimately, these heifers were not exposed to stresses like they would be in a 
feedlot. In the current study, heifers were maintained in a controlled environment. A controlled 
heat stress could give more insight to if the supplementation of ZH is detrimental to the animal’s 
well-being. Furthermore, cattle supplemented ZH in a feedlot might be valuable as well since in 
the current study they were maintained in a barn in individual stalls. A big issue with this idea is 
it would be difficult to collect frequent samples in a feedlot.  
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β-Hydroxybutyrate Assay 
 
Reference: Sigma-Aldrich MAK041 Kit Bulletin, 2012 
 
 
Preparation of Reagents: 
 
Briefly centrifuge vials of each reagent before opening. Be sure to use ultrapure water 
for preparation. Avoid repeated freeze/thaw cycles to maintain integrity.  
 
1. β-Hydroxybutyrate Assay Buffer – Allow to come to room temperature before 
use. 
 
2. β-Hydroxybutyrate Enzyme Mix – Reconstitute with 220µl of β-Hydroxybutyrate 
assay buffer. Mix well via pipette then aliquot and store, protected from light, at -
20°C. Use within 2 months of reconstitution and keep cold while in use. 
 
 
3. β-Hydroxybutyrate Substrate Mix – Reconstitute with 220µl of β-
Hydroxybutyrate assay buffer. Mix well via pipette then aliquot and store, 
protected from light, at -20°C. Use within 2 months of reconstitution and keep 
cold while in use. 
 
 
Preparation of Standards: 
 
1. β-Hydroxybutyrate Standards – Reconstitute with 100µl of water to generate a 
10mM solution. Mix well via pipetting, then aliquot and store, protected from 
light, at -20°C.  
 
2. Dilute 10µl of the 10mM β-Hydroxybutyrate Standard Solution with 90µl β-
Hydroxybutyrate Assay Buffer to prepare a 1mM standard solution. 
 
 
3. For 2 plates mix 50µl of the 10mM β-Hydroxybutyrate Standard Solution with 
450µl of the β-Hydroxybutyrate Assay Buffer. 
 
 
4. In 0.6 ml tubes make up the standards according to the following chart: 
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1mM Standard Solution (l) β-Hydroxybutyrate Assay 
Buffer (l) 
nmole/well Value 
0 400 0 
16 384 2 
32 368 4 
48 352 6 
64 336 8 
80 320 10 
96 304 12 
  
5. Once the standards are made up in the tubes, add 50 µl if the appropriate standard 
into duplicate wells on the plate.  
 
Preparation of Samples: 
 
     Add 8µl of each sample into duplicate wells on the plate. 
     Add 42µl of Assay Buffer to each well to get a final volume of 50 µl 
 
Assay Reaction: 
 
1. Set up the Reaction Mixes according to the scheme below. 50 µl of the 
appropriate Reaction Mix is required for each well in the plate.  
 
Reagent Samples and Standards Blank 
β-Hydroxybutyrate Assay 
Buffer 
46 l 48 l 
β-Hydroxybutyrate Enzyme 
Mix 
2 l - 
β-Hydroxybutyrate 
Substrate Mix 
2 l 2 l 
 
  For 1-96 well plate, mix:  
 4600 µl of β-Hydroxybutyrate Assay Buffer 
 200 µl of β-Hydroxybutyrate Enzyme Mix 
 200 µl of β-Hydroxybutyrate Substrate Mix 
  
2. Add 50 µl of the appropriate Reaction Mix to each of the wells. Mix well using a 
horizontal shaker and incubate the reaction for 20 minutes at room temperature. 
Protect the plate from light during the incubation.  
 
3. Measure the absorbance at 450 nm (A450) on the plate reader using the Beta 
Protocol. 
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Results: 
 
     Calculations:  
     The background for the assays is the value obtained for the 0 (blank) Standard.            
Correct for the background by subtracting the 0 (blank) value from all readings. 
Use the values obtained from the Standards to plot a Standard Curve (A new 
standard curve must be set up each time the assay is run).  Blank values must also 
be subtracted from the sample readings to obtain a corrected measurement. Use 
the corrected value in all calculations. 
 
    Concentration of β-Hydroxybutyrate: 
  
Sa/Sv = C 
Sa = Amount of β-Hydroxybutyrate in unknown sample (nmole) from standard 
curve. 
Sv=Sample volume (l) added into the wells 
     C=Concentration of β-Hydroxybutyrate in sample 
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Lactate Assay 
 
Reference: Sigma-Aldrich MAK064 Kit Bulletin, 2012 
 
Reagent Preparation: 
Lactate Assay Buffer-Allow buffer to come to room temperature before 
use. 
 
Lactate Probe- Warm to room temperature before use. Protect from the 
light. Mix well by pipetting, then aliquot and store at -20°C. 
 
Lactate Enzyme Mix- Reconstitute in 220 µl of Lactate Assay Buffer. Mix 
well via pipette, then aliquot and store at -20° C. Use within 2 months of 
reconstitution.  
 
Preparation of Lactate Standard:  
 
1. Take 10 µl Lactate Standard (100 nmole/µl) and dilute with 990 µl of 
Assay Buffer to result in 1 ml of Diluted Standard (1 nmole/µl). 
 
2. In 0.6 ml tubes make up the standards according to the following 
chart: 
 
Diluted Standard  Lactate Assay Buffer (l) Std. Value (nmole/well)  
0 250 0 
10 240 0.2 
20 230 0.4 
30 220 0.6 
40 210 0.8 
50 200 1.0 
 
3. Once standards are prepared in tubes, add 50 µl of the appropriate 
standard into duplicate wells on the plate.  
 
Preparation of Samples: 
         
1. Samples must be deproteinized using a 10 kDaMWCO spin filter. 
 
2. Add 500µl of sample to filter. 
 
3. Spin tube for 1.5 hours at 14,000g. 
 
4. Remove filter and store sample at -80 °C until ready to use. 
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Assay Reaction: 
1. Set up the Master Reaction Mix according to the following scheme: 
 
Reagent Master Reaction Mix (cell) Master Reaction Mix (plate) 
Lactate Assay Buffer 46 μL 4.600 ml 
Lactate Enzyme Mix 2 μL 200 μL 
Lactate Probe 2 μL 200 μL 
    
2. Add 50 µl of the Master Reaction Mix to each of the duplicate wells.  
 
3. Mix well using a horizontal shaker or by pipetting. 
 
4. Incubate the reaction for 30 minutes at room temperature. Protect the 
plate from light during the incubation 
 
5. Measure the absorbance at 570 nm (A570) 
 
Procedure: 
 
1. Allow Buffer to come to room temperature. Allow Lactate probe to 
come to room temperature (protect from light) 
 
2. Reconstitute Lactate Enzyme Mix in 220 µl of Lactate Assay Buffer, 
mix well 
 
3. Take 10 µl of Lactate Standard and reconstitute with 990 µl of Assay 
Buffer to get your 1 ml of Diluted Standard (1nmole/µl). 
 
4. Prepare standards according to the previous chart. (This should give 
enough standard for 2 plates) 
 
5. Place 50 µl of each standard into duplicate wells on the plate. (Do not 
dilute with assay buffer). 
 
6. Add 3 µl of sample to each duplicate well. 
 
7. Add 47 µl of Lactate Assay Buffer to each well that has a sample in it. 
(Do not add to the standards) 
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8. Make up the Master Reaction Mix according to assay chart in previous 
section (add probe last and use immediately.) 
 
9. Add 50 µl of the Master Reaction Mix to each well. 
 
10. Place plate on incubator/shaker and shake for 1 minute, then continue 
incubating for 29 more minutes. (Protect from light). 
 
11. Measure the absorbance using Lactate Procedure at 570 nm on plate 
reader.  
 
Results:  
 
The background for the assay is the value obtained for the 0 (blank) lactate 
standard.  Correct for the background by subtracting the blank value from all 
readings.  Background values can be significant and must be subtracted from all 
readings. 
 
Use the values obtained from the appropriate lactate standards to plot a standard 
curve.  The amount of lactate present in the samples may be determined from the 
standard curve. 
(Note:  A new standard curve must be set up each time the assay is run.) 
 
Concentration of Lactate: 
 
   Sa/Sv=C 
C x 89.07 ng/nmole = ng/μL 
 
Sa=Amount of lactate acid in unknown sample (nmole) from standard curve 
Sv=Sample volume (μL) added into the wells. 
C=Concentration of lactate acid in sample 
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Lactate Dehydrogenase Assay 
 
Reference:    Sigma-Aldrich MAK066 Kit Bulletin, 2013 
 
Preparation of Reagents:  
Briefly centrifuge vials before opening. Use ultrapure water for the 
preparation of reagents. To maintain reagent integrity, avoid 
repeated freeze/thaw cycles. 
 
1. LDH Assay Buffer:-Allow buffer to come to room temperature 
before use. 
 
2. LDH Substrate Mix- Reconstitute in 1 mL of water. Mix well 
via pipette and keep cold while in use. (Substrate Mix is stable 
for one week at 4 ° C and 1 month at -20°C. 
 
Preparation of NADH Standards:  
1. Reconstitute in 400 µL of water to generate 1.25 mM standard 
solution 
 
2. Mix well via pipette and keep cold while in use. The NADH 
Standard Solution is stable for one week at 4 ° C and 1 month 
at -20°C. 
 
3. In 0.6 mL tubes make up the standards according to the 
following chart: 
 
1.25mM Standard Solution 
(l) 
LDH Assay Buffer (l) nmole/well Value 
0 250 0 
10 240 2.5 
20 230 5 
30 220 7.5 
40 210 10 
50 200 12.5 
 
 
4. Once standards are made up in the tubes, add 50 µL of the 
appropriate standard into duplicate wells on the plate.  
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Preparation of Samples: 
1. Dilute samples in tubes off of the plate : 
 2 µL of sample 
 198 µL of LDH Assay Buffer (dilution factor 100) 
 
2. Then add 50 µL of each diluted sample into duplicate wells on 
the plate (amount of sample going into plate 0.5 µL). 
 
Assay Reaction: 
1. Set up Reaction Mixes according to the scheme below, 50 µL 
of the appropriate Reaction Mix is required for each well. 
 
Reagent Master Reaction Mix 
LDH Assay Buffer 48 l 
LDH Substrate Mix 2 l 
 
2. Add 50 µL of the Master Reaction Mix to each of the wells. 
Protect the plate from light while incubating.  
 
3. Shake 1 minute while incubating.  Incubate an additional minute.  
After these 2 minutes, take the initial measurement (Tinitial).  Measure 
the absorbance at 450 nm at the initial time (A450) initial.  Note:  It is 
essential (A450)initial) is in the linear range of the standard curve. 
 
4. Incubate the plate at 37C taking measurements (A450) every 5 
minutes.  Protect the plate from light during the incubation. 
 
5. Continue taking measurements until the value of the most active 
sample is greater than the value of the highest standard 
(12.5nmole/well).  At this time the most active sample is near or 
exceeds the end of the linear range of the standard curve. 
 
6. The final measurement [(A450) final} for calculating the enzyme 
activity would be penultimate reading or the value before the most 
active sample is near or exceeds the end of the linear range of the 
standard curve.  The time of the penultimate reading is Tfinal. 
Note:  It is essential the final measurement falls within the linear range of the standard curve. 
